<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Tripterygium wilfordii Hook F (a traditional Chinese medicine) for primary nephrotic syndrome - Chen, Y - 2013 | Cochrane Library</title> <meta content="Tripterygium wilfordii Hook F (a traditional Chinese medicine) for primary nephrotic syndrome - Chen, Y - 2013 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008568.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Tripterygium wilfordii Hook F (a traditional Chinese medicine) for primary nephrotic syndrome - Chen, Y - 2013 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008568.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008568.pub2" name="dc.identifier" scheme="DOI"/> <meta content="&lt;i&gt;Tripterygium wilfordii&lt;/i&gt; Hook F (a traditional Chinese medicine) for primary nephrotic syndrome" name="citation_title"/> <meta content="Yizhi Chen" name="citation_author"/> <meta content="Chinese People's Liberation Army (PLA) General Hospital (301 Hospital), Chinese PLA Medical Academy" name="citation_author_institution"/> <meta content="Zhixiang Gong" name="citation_author"/> <meta content="Chinese PLA 532 Hospital" name="citation_author_institution"/> <meta content="Xiangmei Chen" name="citation_author"/> <meta content="Chinese People's Liberation Army (PLA) General Hospital (301 Hospital), Chinese PLA Medical Academy" name="citation_author_institution"/> <meta content="Li Tang" name="citation_author"/> <meta content="Chinese People's Liberation Army (PLA) General Hospital (301 Hospital), Chinese PLA Medical Academy" name="citation_author_institution"/> <meta content="Xuezhi Zhao" name="citation_author"/> <meta content="Shanghai Chang Zheng Hospital" name="citation_author_institution"/> <meta content="Qing Yuan" name="citation_author"/> <meta content="309th Hospital of the People's Liberation Army" name="citation_author_institution"/> <meta content="Guangyan Cai" name="citation_author"/> <meta content="Chinese People's Liberation Army (PLA) General Hospital (301 Hospital), Chinese PLA Medical Academy" name="citation_author_institution"/> <meta content="caiguangyan@sina.com" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD008568.pub2" name="citation_doi"/> <meta content="2013" name="citation_date"/> <meta content="2013/08/11" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008568.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008568.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008568.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Cyclophosphamide [therapeutic use]; Drugs, Chinese Herbal [adverse effects, *therapeutic use]; Immunosuppressive Agents [adverse effects, *therapeutic use]; Nephrotic Syndrome [*drug therapy]; Phytotherapy [*methods]; Prednisone [adverse effects, therapeutic use]; Randomized Controlled Trials as Topic; Remission Induction [methods]; *Tripterygium [adverse effects]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008568.pub2&amp;doi=10.1002/14651858.CD008568.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008568.pub2&amp;doi=10.1002/14651858.CD008568.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008568.pub2&amp;doi=10.1002/14651858.CD008568.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008568.pub2&amp;doi=10.1002/14651858.CD008568.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008568.pub2&amp;doi=10.1002/14651858.CD008568.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008568.pub2&amp;doi=10.1002/14651858.CD008568.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008568.pub2&amp;doi=10.1002/14651858.CD008568.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008568.pub2&amp;doi=10.1002/14651858.CD008568.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008568.pub2&amp;doi=10.1002/14651858.CD008568.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008568.pub2&amp;doi=10.1002/14651858.CD008568.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008568.pub2&amp;doi=10.1002/14651858.CD008568.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008568.pub2&amp;doi=10.1002/14651858.CD008568.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008568.pub2&amp;doi=10.1002/14651858.CD008568.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008568.pub2&amp;doi=10.1002/14651858.CD008568.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008568.pub2&amp;doi=10.1002/14651858.CD008568.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008568.pub2&amp;doi=10.1002/14651858.CD008568.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008568.pub2&amp;doi=10.1002/14651858.CD008568.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008568.pub2&amp;doi=10.1002/14651858.CD008568.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008568.pub2&amp;doi=10.1002/14651858.CD008568.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008568.pub2&amp;doi=10.1002/14651858.CD008568.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008568.pub2&amp;doi=10.1002/14651858.CD008568.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008568.pub2&amp;doi=10.1002/14651858.CD008568.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008568.pub2&amp;doi=10.1002/14651858.CD008568.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="PSzzz2OT";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008568\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008568\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008568\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008568\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ko","ja","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008568.pub2",title:"\u003ci\u003eTripterygium wilfordii\u003c/i\u003e Hook F (a traditional Chinese medicine) for primary nephrotic syndrome",firstPublishedDate:"Aug 11, 2013 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Kidney and Transplant Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PSzzz2OT&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008568.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008568.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008568.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008568.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008568.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008568.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;アブストラクト&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008568.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008568.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008568.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008568.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3197 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008568.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008568.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008568.pub2/full#CD008568-abs-0006"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008568.pub2/full#CD008568-sec1-0007"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008568.pub2/full#CD008568-sec1-0001"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008568.pub2/full#CD008568-sec1-0002"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008568.pub2/full#CD008568-sec1-0003"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008568.pub2/full#CD008568-sec1-0004"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008568.pub2/full#CD008568-sec1-0005"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008568.pub2/full#CD008568-sec1-0006"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008568.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008568.pub2/appendices#CD008568-sec1-0012"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008568.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008568.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/table_n/CD008568StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/table_n/CD008568StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008568.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008568.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008568.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008568.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008568.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008568.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2013 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en"><i>Tripterygium wilfordii</i> Hook F (a traditional Chinese medicine) for primary nephrotic syndrome </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008568.pub2/information#CD008568-cr-0002">Yizhi Chen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008568.pub2/information#CD008568-cr-0003">Zhixiang Gong</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008568.pub2/information#CD008568-cr-0004">Xiangmei Chen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008568.pub2/information#CD008568-cr-0005">Li Tang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008568.pub2/information#CD008568-cr-0006">Xuezhi Zhao</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008568.pub2/information#CD008568-cr-0007">Qing Yuan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008568.pub2/information#CD008568-cr-0008"><i class="icon corresponding-author fa fa-envelope"></i>Guangyan Cai</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/information/en#CD008568-sec1-0015">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 11 August 2013 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008568.pub2">https://doi.org/10.1002/14651858.CD008568.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008568-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008568-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008568-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/ja#CD008568-abs-0003">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD008568-abs-0002">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008568-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008568-abs-0001" lang="en"> <section id="CD008568-abs1-0001"> <h3 class="title" id="CD008568-abs1-0001">Background</h3> <p><i>Tripterygium wilfordii</i> Hook F (TwHF), a traditional Chinese herbal medicine used as an immunosuppressive agent, has been prescribed in China for patients with primary nephrotic syndrome (NS) for more than two decades. Although patients with primary NS in China have benefited from TwHF treatment, its properties have not yet been fully understood. </p> </section> <section id="CD008568-abs1-0002"> <h3 class="title" id="CD008568-abs1-0002">Objectives</h3> <p>To assess the benefits and harms of TwHF for patients with primary NS.</p> </section> <section id="CD008568-abs1-0003"> <h3 class="title" id="CD008568-abs1-0003">Search methods</h3> <p>We searched the Cochrane Renal Group's specialised register (August 2012), Cochrane Register of Controlled Trials (CENTRAL, <i>The Cochrane Library</i> 2012, Issue 8), EMBASE (1966 to August 2012), and MEDLINE (1966 to August 2012). We also searched CBM (Chinese Biological Medical Database) (1978 to November 2010), CNKI (Chinese National Knowledge Infrastructure) (1979 to November 2010), VIP (ChongQing WeiPu Chinese Science and Technology Periodical Database) (1989 to November 2010), WanFang Database (1980 to November 2010), and reference lists of articles (6 November 2010). </p> </section> <section id="CD008568-abs1-0004"> <h3 class="title" id="CD008568-abs1-0004">Selection criteria</h3> <p>Only randomised controlled trials (RCTs) were included. Two standardised preparations of TwHF were investigated: ethanol‐ethyl acetate extract and chloroform‐methanol extract. All other TwHF preparations were excluded because of reported toxicities. Other traditional Chinese herbal medicines were also excluded. All included RCTs had a follow‐up of at least three months. </p> </section> <section id="CD008568-abs1-0005"> <h3 class="title" id="CD008568-abs1-0005">Data collection and analysis</h3> <p>Data extraction and risk of bias assessment were undertaken independently by two authors. Where details of randomised sequence generation and allocation concealment were absent or inadequately reported, we contacted original study investigators for verification and details of the procedure. For dichotomous outcomes (remission and drug‐related adverse events) we used risk ratio (RR) with 95% confidence intervals (95% CI) and mean difference (MD) for continuous outcomes (urinary protein excretion, serum albumin and serum creatinine). </p> </section> <section id="CD008568-abs1-0006"> <h3 class="title" id="CD008568-abs1-0006">Main results</h3> <p>Ten studies enrolling 630 participants were included. Overall, the quality of evidence was suboptimal due to the small number of included studies enrolling small numbers of participants; short follow‐up in each study; only a few studies in each comparison category; and major concerns with methodological bias. Four studies (293 participants) contributed to the comparison of TwHF versus non‐TwHF. TwHF significantly increased complete remission (RR 1.46, 95% CI 1.18 to 1.80) and complete or partial remission (RR 1.26, 95% CI 1.10 to 1.44) without escalating the adverse events profile at the last follow‐up (12 to 16 months). Four studies (223 participants) compared TwHF with prednisone. There were no statistically significant differences between complete remission, partial remission, and complete or partial remission. Two studies (114 participants) contributed to the comparison of TwHF versus cyclophosphamide (CPA) at the last follow‐up (3 to 12 months). There were no statistically significant differences between complete, partial, or complete or partial remission. One study (46 participants) reported TwHF was associated with a significantly lower serum creatinine compared with CPA (MD ‐14.00 μmol/L, 95% CI ‐26.43 to ‐1.57). No serious adverse events of TwHF were observed. One study (37 participants) reported TwHF was associated with a significantly lower risk of psychosis when compared to prednisone (RR 0.11, 95% CI 0.01 to 0.75), and two studies showed a significantly lower risk of hair loss with TwHF when compared to CPA ((2 studies, 114 participants): RR 0.11, 95% CI 0.02 to 0.59). </p> </section> <section id="CD008568-abs1-0007"> <h3 class="title" id="CD008568-abs1-0007">Authors' conclusions</h3> <p>TwHF may have an add‐on effect on remission in patients with primary NS. There was insufficient evidence to assess if TwHF was as effective as prednisone or CPA. More methodologically sound and sufficiently powered studies, with adequate follow‐up would help to better inform management options for the use of TwHF for primary NS. TwHF should be further directly compared with other widely used immunosuppressive agents after the superiority over placebo or no treatment has been clearly established. </p> </section> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008568-abs-0006" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008568-abs-0006">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008568-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/ja#CD008568-abs-0008">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD008568-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008568-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008568-abs-0006" lang="en"> <h3>Tripterygium wilfordii Hook F (a traditional Chinese herbal medicine) for primary nephrotic syndrome </h3> <p>Primary nephrotic syndrome (NS) is a relatively rare kidney disease (diagnosed in up to 7/100,000 children and 3/100,000 adults annually). However the resulting kidney damage causes loss of proteins in urine (proteinuria) leading to low level albumin in the bloodstream, which can cause raised lipids and severe, generalised swelling. Primary NS can also lead to blood clotting (thromboembolism), infection, and acute kidney injury, and may become life threatening. Treatment for primary NS aims to relieve symptoms, avoid complications, and prolong life. Immunosuppressive treatments are of importance for primary NS. In China, a traditional Chinese herbal medicine, <i>Tripterygium wilfordii</i> Hook F (TwHF) has been used for over two decades as an immunosuppressive agent to decrease proteinuria and preserve kidney function. TwHF is prescribed alone or in combination with corticosteroids or other immunosuppressive agents such as cyclophosphamide (CPA). </p> <p>In this review we investigated the use of TwHF as an immunosuppressive therapy for patients with primary NS. We only considered two standardised TwHF extracts which have lower toxicity profiles and fewer adverse effects than other non‐standardised preparations. We reviewed the evidence from 10 randomised studies enrolling 630 Chinese patients with primary NS. Of these, four studies (293 patients) reported that when TwHF was used there was a significantly increased number of patients achieving complete, and complete or partial remission without increasing adverse events. There were no significant differences in complete, partial, or complete or partial remission when TwHF was compared with prednisone in four studies (223 patients). There were also no significant differences in complete, partial, or complete or partial remission when TwHF was compared with CPA in two studies (114 patients). One study reported TwHF significantly improved kidney function (decreased serum creatinine) when compared with CPA. TwHF was associated with a lower risk of psychosis than prednisone; and there was less likelihood of hair loss when compared to CPA. The quality of evidence was poor; there were only 10 studies, enrolling a total of 630 patients; follow‐up was short; the maximum number of studies included in a comparison was four; and we had major concerns over the quality of the included studies. TwHF may have an add‐on effect on remission in patients with primary NS; however there is insufficient evidence to assess if TwHF is as effective as prednisone or CPA. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008568-sec1-0007" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008568-sec1-0007"></div> <h3 class="title" id="CD008568-sec1-0008">Implications for practice</h3> <section id="CD008568-sec1-0008"> <p>Overall, the quality of evidence was suboptimal due to the small number of included studies enrolling small numbers of participants; short follow‐up in each study; only a few studies in each comparison category; and major concerns with methodological bias. This review has highlighted the fact that no well‐designed RCT has been performed to test the efficacy and safety of TwHF for primary NS. In the majority of the included studies TwHF was used in conjunction with other immunosuppressive agents such as prednisone and CPA. Therefore, the individual effect of TwHF is still unclear. TwHF may have an add‐on effect on remission in patients with primary NS. There was insufficient evidence to assess if TwHF was as effective as prednisone or CPA. </p> </section> <h3 class="title" id="CD008568-sec1-0009">Implications for research</h3> <section id="CD008568-sec1-0009"> <p>There is need for more methodologically sound studies with an emphasis on adequate sample size and follow‐up. Furthermore, priority should be given to the choice of definite endpoints (all‐cause mortality, risk of end‐stage kidney disease) rather than surrogate outcomes (decline in kidney function). Recording and reporting adverse events should also be improved in future clinical studies. TwHF should be further directly compared with other widely used immunosuppressive agents after the superiority over placebo or no treatment has been clearly established. Ideally, optimal doses and durations of TwHF treatment that are most beneficial and least harmful to patients of different races, ages, and clinical and pathological severity still remain to be clarified. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008568-sec1-0001" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008568-sec1-0001"></div> <div class="table" id="CD008568-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings: Tripterygium wilfordii Hook F (TwHF) versus no TwHF</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="6" rowspan="1" valign=""> <p><b> TwHF versus non‐TwHF for primary nephrotic syndrome</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="6" rowspan="1" valign=""> <p><b> Patient or population: patients with primary nephrotic syndrome<br/> Settings: <br/> Intervention: <i>Tripterygium wilfordii</i> Hook F (TwHF)<br/> Comparison: no TwHF</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Non‐TwHF</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> TwHF</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Complete remission</b> (follow‐up: 12 to 16 months) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.46</b> <br/> (1.18 to 1.80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>293 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>436 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>637 per 1000</b> <br/> (514 to 785) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>406 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>593 per 1000</b> <br/> (479 to 731) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Partial remission</b> (follow‐up: 12 to 16 months) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.77</b> <br/> (0.49 to 1.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>293 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>229 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>176 per 1000</b> <br/> (112 to 277) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>257 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>198 per 1000</b> <br/> (126 to 311) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Complete or partial remission</b> (follow‐up: 12 to 16 months) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.26</b> <br/> (1.1 to 1.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>293 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>664 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>837 per 1000</b> <br/> (730 to 956) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>662 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>834 per 1000</b> <br/> (728 to 953) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/> <b>Very low quality:</b> we are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Small number of studies and patients, short follow‐up, and major concerns with methodological bias.<br/> <sup>2</sup> Language bias should be considered because all included studies were conducted in Chinese patients and published in Chinese language. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008568-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings: Tripterygium wilfordii Hook F versus prednisone</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="6" rowspan="1" valign=""> <p><b><i>Tripterygium wilfordii</i> Hook F (TwHF) versus prednisone for primary nephrotic syndrome</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="6" rowspan="1" valign=""> <p><b> Patient or population: patients with primary nephrotic syndrome<br/> Settings: <br/> Intervention: TwHF<br/> Comparison: prednisone</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Prednisone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> TwHF</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Complete remission</b> (follow‐up: 6 to 18 months) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.09</b> <br/> (0.83 to 1.43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>223 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>462 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>504 per 1000</b> <br/> (383 to 661) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>545 per 1000</b> <br/> (415 to 715) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Partial remission</b> (follow‐up: 6 to 18 months) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.07</b> <br/> (0.69 to 1.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>223 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>269 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>288 per 1000</b> <br/> (186 to 444) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>290 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>310 per 1000</b> <br/> (200 to 478) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Complete or partial remission</b> (follow‐up: 6 to 18 months) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.05</b> <br/> (0.92 to 1.2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>223 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>731 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>768 per 1000</b> <br/> (673 to 877) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>722 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>758 per 1000</b> <br/> (664 to 866) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/> <b>Very low quality:</b> we are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Small number of studies and patients, short follow‐up, and major concerns with methodological bias.<br/> <sup>2</sup> Language bias should be considered because all included studies were conducted in Chinese patients and published in Chinese language. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008568-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings: Comparison of TwHF and CPA</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="6" rowspan="1" valign=""> <p><b><i>Tripterygium wilfordii</i> Hook F (TwHF)versus cyclophosphamide (CPA)for primary nephrotic syndrome</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="6" rowspan="1" valign=""> <p><b> Patient or population: patients with primary nephrotic syndrome<br/> Settings: <br/> Intervention: TwHF<br/> Comparison: CPA</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>CPA</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> TwHF</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Complete remission</b> (follow‐up: 3 to 12 months) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.06</b> <br/> (0.82 to 1.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>114 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>654 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>693 per 1000</b> <br/> (536 to 896) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>653 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>692 per 1000</b> <br/> (535 to 895) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Partial remission</b> (follow‐up: 3 to 12 months) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.02</b> <br/> (0.46 to 2.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>114 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>173 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>176 per 1000</b> <br/> (80 to 396) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>169 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>172 per 1000</b> <br/> (78 to 387) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Complete or partial remission</b> (follow‐up: 3 to 12 months) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.05</b> <br/> (0.9 to 1.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>114 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>827 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>868 per 1000</b> <br/> (744 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>822 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>863 per 1000</b> <br/> (740 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) was based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/> <b>Very low quality:</b> we are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Small number of studies and patients, short follow‐up, and major concerns with methodological bias.<br/> <sup>2</sup> Language bias should be considered because all included studies were conducted in Chinese patients and published in Chinese language </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008568-sec1-0002" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008568-sec1-0002"></div> <section id="CD008568-sec2-0001"> <h3 class="title" id="CD008568-sec2-0001">Description of the condition</h3> <p>Primary nephrotic syndrome (NS) is a relatively rare, but important kidney disease in children and adults (<a href="./references#CD008568-bbs2-0055" title="EddyAA , SymonsJM . Nephrotic syndrome in childhood. Lancet2003;362(9384):629‐39. [MEDLINE: 12944064] ">Eddy 2003</a>; <a href="./references#CD008568-bbs2-0061" title="HullRP , GoldsmithDJ . Nephrotic syndrome in adults. BMJ2008;336(7654):1185‐9. [MEDLINE: 18497417] ">Hull 2008</a>). It has an annual incidence of 2 to 7/100,000 children (<a href="./references#CD008568-bbs2-0055" title="EddyAA , SymonsJM . Nephrotic syndrome in childhood. Lancet2003;362(9384):629‐39. [MEDLINE: 12944064] ">Eddy 2003</a>) and 3/100,000 adults (<a href="./references#CD008568-bbs2-0061" title="HullRP , GoldsmithDJ . Nephrotic syndrome in adults. BMJ2008;336(7654):1185‐9. [MEDLINE: 18497417] ">Hull 2008</a>). There are five main distinct histological variants of primary NS: minimal change nephropathy (MCN); focal segmental glomerulosclerosis (FSGS); membranous nephropathy (MN); mesangioproliferative glomerulonephritis (MsPGN) (immunoglobulin A (IgA) nephropathy and non‐IgA nephropathy); and membranoproliferative glomerulonephritis (MPGN). Acute complications related to primary NS include thromboembolism, infection, and acute kidney injury (AKI). Deep and renal vein thromboses could lead to pulmonary embolism. Bacterial and viral infections such as pneumonia and cellulitis are an ongoing threat to the health of immunocompromised patients. Long‐term sequelae of primary NS relate mainly to adverse events of immunosuppressive treatments on bones, growth and the cardiovascular system (<a href="./references#CD008568-bbs2-0055" title="EddyAA , SymonsJM . Nephrotic syndrome in childhood. Lancet2003;362(9384):629‐39. [MEDLINE: 12944064] ">Eddy 2003</a>; <a href="./references#CD008568-bbs2-0061" title="HullRP , GoldsmithDJ . Nephrotic syndrome in adults. BMJ2008;336(7654):1185‐9. [MEDLINE: 18497417] ">Hull 2008</a>). </p> </section> <section id="CD008568-sec2-0002"> <h3 class="title" id="CD008568-sec2-0002">Description of the intervention</h3> <p><i>Tripterygium wilfordii</i> Hook F (TwHF) has been used widely in traditional Chinese medicine to treat rheumatoid arthritis and other autoimmune and inflammatory diseases. Results from studies in Chinese patients (<a href="./references#CD008568-bbs2-0071" title="TaoXL , DongY , ZhangNZ . A double‐blind study of T2 (tablets of polyglycosides of Tripterygium wilfordii hook) in the treatment of rheumatoid arthritis. Zhonghua Nei Ke Za Zhi [Chinese Journal of Internal Medicine]1987;26(7):399‐402, 44‐5. [MEDLINE: 3322706] ">Tao 1987</a>; <a href="./references#CD008568-bbs2-0072" title="TaoXL , SunY , DongY , XiaoYL , HuDW , ShiYP , et al. A prospective, controlled, double‐blind, cross‐over study of Tripterygium wilfordii hook F in treatment of rheumatoid arthritis. Chinese Medical Journal (English)1989;102(5):327‐32. [MEDLINE: 2509153] ">Tao 1989</a>) stimulated further investigation of TwHF for rheumatoid arthritis in western countries (<a href="./references#CD008568-bbs2-0056" title="Goldbach‐ManskyR , WilsonM , FleischmannR , OlsenN , SilverfieldJ , KempfP , et al. Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial. Annals of Internal Medicine2009;151(4):229‐40, W49‐51. [MEDLINE: 19687490] ">Goldbach‐Mansky 2009</a>; <a href="./references#CD008568-bbs2-0075" title="TaoX , CushJJ , GarretM , LipskyPE . A phase I study of ethyl acetate extract of the Chinese antirheumatic herb Tripterygium wilfordii hook F in rheumatoid arthritis. Journal of Rheumatology2001;28(10):2160‐7. [MEDLINE: 11669150] ">Tao 2001</a>; <a href="./references#CD008568-bbs2-0076" title="TaoX , YoungerJ , FanFZ , WangB , LipskyPE . Benefit of an extract of Tripterygium Wilfordii Hook F in patients with rheumatoid arthritis: a double‐blind, placebo‐controlled study. Arthritis &amp; Rheumatism2002;46(7):1735‐43. [MEDLINE: 12124856] ">Tao 2002</a>). TwHF has been prescribed as an immunosuppressive agent for primary NS in China for more than 20 years (<a href="./references#CD008568-bbs2-0053" title="ChenSY . Effect of Tripterygium wilfordii on the remission of proteinuria in patients with nephrotic syndrome. Zhongguo Zhongxiyi Jiehe Zazhi [Chinese Journal of Integrated Traditional and Western Medicine]1985;5(3):164‐6, 132. [MEDLINE: 3157498] ">Chen 1985</a>; <a href="./references#CD008568-bbs2-0063" title="JiangX . Clinical observations on the use of the Chinese herb Tripterygium wilfordii Hook for the treatment of nephrotic syndrome. Pediatric Nephrology1994;8(3):343‐4. [MEDLINE: 7917863] ">Jiang 1994</a>). Preliminary observations suggested that remission was achieved in 8/13 (62%) children with primary NS and maintained in four children (31%) for up to three years (<a href="./references#CD008568-bbs2-0063" title="JiangX . Clinical observations on the use of the Chinese herb Tripterygium wilfordii Hook for the treatment of nephrotic syndrome. Pediatric Nephrology1994;8(3):343‐4. [MEDLINE: 7917863] ">Jiang 1994</a>). A meta‐analysis of three studies enrolling 150 adult patients with primary refractory NS indicated that TwHF were associated with a higher complete remission (Odds ratio (OR) 2.81, 95% CI 1.26 to 6.30) and complete or partial remission (OR 3.25, 95% CI 1.20 to 8.76) (<a href="./references#CD008568-bbs2-0080" title="XuG , TuW , JiangD , XuC . Tripterygium wilfordii Hook F treatment for idiopathic refractory nephrotic syndrome in adults: a meta‐analysis. Nephron. Clinical Practice2009;111(4):c223‐8. [MEDLINE: 19287181] ">Xu 2009a</a>). </p> <p>Non‐standardised TwHF preparations have been reported as causing serious adverse events and death (<a href="./references#CD008568-bbs2-0079" title="WenZH , XuWH , LaiSL . Causal relationship of adverse reactions with tripterygium in 38 patients. Zhongyao Xinyao Yu Linchuang Yaoli [Traditional Chinese Drug Research &amp; Clinical Pharmacology]1999;10(1):50‐3. ">Wen 1999</a>). A search of the Chinese Biological Medicine (CBM) Database (from 1982 to 1996) identified 38 patients who experienced adverse events related to non‐standardised TwHF preparations (<a href="./references#CD008568-bbs2-0079" title="WenZH , XuWH , LaiSL . Causal relationship of adverse reactions with tripterygium in 38 patients. Zhongyao Xinyao Yu Linchuang Yaoli [Traditional Chinese Drug Research &amp; Clinical Pharmacology]1999;10(1):50‐3. ">Wen 1999</a>). The adverse events included leukopenia (9/38, 24%), aplastic anaemia (5/38, 13%), gastrointestinal tract disturbances (10/38, 26%), liver dysfunction (4/38, 11%), skin lesions such as erythema and papules (5/38, 13%) and other rare complications. Serious adverse events were primarily related to haematological system, and 8/38 (21%) died (leukopenia (4/8, 50%); aplastic anaemia (2/8, 25%); severe liver dysfunction (2/8, 25%)) (<a href="./references#CD008568-bbs2-0079" title="WenZH , XuWH , LaiSL . Causal relationship of adverse reactions with tripterygium in 38 patients. Zhongyao Xinyao Yu Linchuang Yaoli [Traditional Chinese Drug Research &amp; Clinical Pharmacology]1999;10(1):50‐3. ">Wen 1999</a>). Toxicities caused by non‐standardised TwHF preparations which were reported before 1996 were difficult to compare with adverse events reported for standardised TwHF preparations such as ethanol‐ethyl acetate and chloroform‐methanol extracts of TwHF (<a href="./references#CD008568-bbs2-0056" title="Goldbach‐ManskyR , WilsonM , FleischmannR , OlsenN , SilverfieldJ , KempfP , et al. Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial. Annals of Internal Medicine2009;151(4):229‐40, W49‐51. [MEDLINE: 19687490] ">Goldbach‐Mansky 2009</a>). Peeling the roots of this plant and using a standardised extraction method can fundamentally reduce toxicity and increase tolerability (<a href="./references#CD008568-bbs2-0076" title="TaoX , YoungerJ , FanFZ , WangB , LipskyPE . Benefit of an extract of Tripterygium Wilfordii Hook F in patients with rheumatoid arthritis: a double‐blind, placebo‐controlled study. Arthritis &amp; Rheumatism2002;46(7):1735‐43. [MEDLINE: 12124856] ">Tao 2002</a>). More recently, the most common adverse events of standardised TwHF preparations were gastrointestinal tract disturbances, leukopenia, thrombocytopenia, rash, skin pigmentation, and malfunction of reproductive system (<a href="./references#CD008568-bbs2-0051" title="BaoJ , DaiSM . A Chinese herb Tripterygium wilfordii Hook F in the treatment of rheumatoid arthritis: mechanism, efficacy, and safety. Rheumatology International2011;31(9):1123‐9. [MEDLINE: 21365177] ">Bao 2011</a>). Most of these could be resolved by dose adjustment or drug discontinuation (<a href="./references#CD008568-bbs2-0051" title="BaoJ , DaiSM . A Chinese herb Tripterygium wilfordii Hook F in the treatment of rheumatoid arthritis: mechanism, efficacy, and safety. Rheumatology International2011;31(9):1123‐9. [MEDLINE: 21365177] ">Bao 2011</a>; <a href="./references#CD008568-bbs2-0056" title="Goldbach‐ManskyR , WilsonM , FleischmannR , OlsenN , SilverfieldJ , KempfP , et al. Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial. Annals of Internal Medicine2009;151(4):229‐40, W49‐51. [MEDLINE: 19687490] ">Goldbach‐Mansky 2009</a>). </p> </section> <section id="CD008568-sec2-0003"> <h3 class="title" id="CD008568-sec2-0003">How the intervention might work</h3> <p><a href="./references#CD008568-bbs2-0066" title="KupchanSM , CourtWA , DaileyRG , Jr , GilmoreCJ , BryanRF . Triptolide and tripdiolide, novel antileukemic diterpenoid triepoxides from Tripterygium wilfordii. Journal of the American Chemical Society1972;94(20):7194‐5. [MEDLINE: 5072337] ">Kupchan 1972</a> first demonstrated that triptolide and tripdiolide, two diterpenoid triepoxides from TwHF, possess antileukaemic properties. More recently, triptolide and tripdiolide were considered to be the principal active components of TwHF (<a href="./references#CD008568-bbs2-0073" title="TaoX , CaiJJ , LipskyPE . The identity of immunosuppressive components of the ethyl acetate extract and chloroform methanol extract (T2) of Tripterygium wilfordii Hook. F. Journal of Pharmacology &amp; Experimental Therapeutics1995;272(3):1305‐12. [MEDLINE: 7891348] ">Tao 1995</a>). Two preparations of TwHF have been used extensively in experimental and clinical studies because of their lower toxicity profiles: chloroform‐methanol extract (T2 or TwHF multiglycoside) and ethanol‐ethyl acetate extract (<a href="./references#CD008568-bbs2-0056" title="Goldbach‐ManskyR , WilsonM , FleischmannR , OlsenN , SilverfieldJ , KempfP , et al. Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial. Annals of Internal Medicine2009;151(4):229‐40, W49‐51. [MEDLINE: 19687490] ">Goldbach‐Mansky 2009</a>; <a href="./references#CD008568-bbs2-0069" title="SharmaM , LiJZ , SharmaR , ArteroM , GeX , McCarthyET , et al. Inhibitory effect of Tripterygium wilfordii multiglycoside on increased glomerular albumin permeability in vitro. Nephrology Dialysis Transplantation1997;12(10):2064‐8. [MEDLINE: 9351066] ">Sharma 1997</a>; <a href="./references#CD008568-bbs2-0074" title="TaoX , Schulze‐KoopsH , MaL , CaiJ , MaoY , LipskyPE . Effects of Tripterygium wilfordii hook F extracts on induction of cyclooxygenase 2 activity and prostaglandin E2 production. Arthritis &amp; Rheumatism1998;41(1):130‐8. [MEDLINE: 9433878] ">Tao 1998</a>; <a href="./references#CD008568-bbs2-0075" title="TaoX , CushJJ , GarretM , LipskyPE . A phase I study of ethyl acetate extract of the Chinese antirheumatic herb Tripterygium wilfordii hook F in rheumatoid arthritis. Journal of Rheumatology2001;28(10):2160‐7. [MEDLINE: 11669150] ">Tao 2001</a>; <a href="./references#CD008568-bbs2-0076" title="TaoX , YoungerJ , FanFZ , WangB , LipskyPE . Benefit of an extract of Tripterygium Wilfordii Hook F in patients with rheumatoid arthritis: a double‐blind, placebo‐controlled study. Arthritis &amp; Rheumatism2002;46(7):1735‐43. [MEDLINE: 12124856] ">Tao 2002</a>; <a href="./references#CD008568-bbs2-0078" title="WanY , SunW , ZhangH , YanQ , ChenP , DouC , et al. Multi‐glycoside of Tripterygium wilfordii Hook F. ameliorates prolonged mesangial lesions in experimental progressive glomerulonephritis. Nephron. Experimental Nephrology2010;114(1):e7‐14. [MEDLINE: 19816047] ">Wan 2010</a>). </p> <p><a href="./references#CD008568-bbs2-0069" title="SharmaM , LiJZ , SharmaR , ArteroM , GeX , McCarthyET , et al. Inhibitory effect of Tripterygium wilfordii multiglycoside on increased glomerular albumin permeability in vitro. Nephrology Dialysis Transplantation1997;12(10):2064‐8. [MEDLINE: 9351066] ">Sharma 1997</a> demonstrated the in vitro inhibitory effect of chloroform‐methanol extract on increased glomerular albumin permeability in isolated glomeruli. The protective effect of chloroform‐methanol extract on glomerular filtration barriers may be independent from anti‐inflammatory and immunosuppressive properties of TwHF (<a href="./references#CD008568-bbs2-0069" title="SharmaM , LiJZ , SharmaR , ArteroM , GeX , McCarthyET , et al. Inhibitory effect of Tripterygium wilfordii multiglycoside on increased glomerular albumin permeability in vitro. Nephrology Dialysis Transplantation1997;12(10):2064‐8. [MEDLINE: 9351066] ">Sharma 1997</a>). <a href="./references#CD008568-bbs2-0060" title="HongY , ZhouW , LiK , SacksSH . Triptolide is a potent suppressant of C3, CD40 and B7h expression in activated human proximal tubular epithelial cells. Kidney International2002;62(4):1291‐300. [MEDLINE: 12234299] ">Hong 2002</a> showed that in vitro triptolide could effectively inhibit the pro‐inflammatory and immunoregulatory potential of TNF‐α activated human renal proximal tubular epithelial cells by inhibiting C3, B7h, and CD40 expression. The chloroform‐methanol extract, presumably through reducing production of injurious cytokines, ameliorated proteinuria and acute mesangial injury in Thy1.1 glomerulonephritis rat model (<a href="./references#CD008568-bbs2-0077" title="WanY , GuL , SuzukiK , KarasawaT , FujiokaY , HanGD , et al. Multi‐glycoside of Tripterygium wilfordii Hook f. ameliorates proteinuria and acute mesangial injury induced by anti‐Thy1.1 monoclonal antibody. Nephron. Experimental Nephrology2005;99(4):e121‐9. [MEDLINE: 15722645] ">Wan 2005</a>). Triptolide displayed a prominent in vivo anti‐proteinuric effect in puromycin aminonucleoside (PAN)‐induced nephrosis rat model characterised by improvement of foot process effacement, decrease of podocyte injury marker (desmin) and restoration of nephrin and podocin expression and distribution (<a href="./references#CD008568-bbs2-0081" title="ZhengCX , ChenZH , ZengCH , QinWS , LiLS , LiuZH . Triptolide protects podocytes from puromycin aminonucleoside induced injury in vivo and in vitro. Kidney International2008;74(5):596‐612. [MEDLINE: 18509322] ">Zheng 2008</a>). This in vitro study further confirmed the protective effect of triptolide on immortalised mouse podocytes from PAN‐induced disruption of actin cytoskeleton and microfilament‐associated synaptopodin and abnormality of nephrin and podocin expression (<a href="./references#CD008568-bbs2-0081" title="ZhengCX , ChenZH , ZengCH , QinWS , LiLS , LiuZH . Triptolide protects podocytes from puromycin aminonucleoside induced injury in vivo and in vitro. Kidney International2008;74(5):596‐612. [MEDLINE: 18509322] ">Zheng 2008</a>). The effects of triptolide may be attributed to the suppression of reactive oxygen species generation and subsequent p38 mitogen‐activated protein kinase pathway activation, and restoration of RhoA activity (<a href="./references#CD008568-bbs2-0081" title="ZhengCX , ChenZH , ZengCH , QinWS , LiLS , LiuZH . Triptolide protects podocytes from puromycin aminonucleoside induced injury in vivo and in vitro. Kidney International2008;74(5):596‐612. [MEDLINE: 18509322] ">Zheng 2008</a>). </p> </section> <section id="CD008568-sec2-0004"> <h3 class="title" id="CD008568-sec2-0004">Why it is important to do this review</h3> <p>Although TwHF has been used widely as an immunosuppressive agent for primary NS in China for more than 20 years, the efficacy and safety of TwHF have not been systematically reviewed. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008568-sec1-0003" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008568-sec1-0003"></div> <p>This review aimed to assess the benefits and harms of TwHF for the treatment of primary NS in adults and children, either as a sole agent or combined with other drug therapies. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008568-sec1-0004" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008568-sec1-0004"></div> <section id="CD008568-sec2-0005"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008568-sec3-0001"> <h4 class="title">Types of studies</h4> <p>All randomised controlled trials (RCTs) investigating the efficacy and safety of TwHF administered to patients with primary NS were considered for inclusion. Quasi‐RCTs (studies in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods) were excluded. All the included RCTs had a follow‐up of at least three months. </p> </section> <section id="CD008568-sec3-0002"> <h4 class="title">Types of participants</h4> <section id="CD008568-sec4-0001"> <h5 class="title">Inclusion criteria</h5> <p>Adult and children diagnosed with primary NS were included. The diagnosis of NS were defined by the authors in each single study. In absence of an explicit definition of primary NS, proteinuria above 3.5 g/24 h was used as the cut‐off value for adults, and in children urine protein‐creatinine ratio above 200 mg/mmol, proteinuria above 300mg/dL, or protein on urine dipstick above 3+ was used (<a href="./references#CD008568-bbs2-0064" title="KDIGO . Idiopathic membranous nephropathy. Kidney International ‐ Supplement2012;2:186‐97. ">KDIGO 2012</a>). </p> </section> <section id="CD008568-sec4-0002"> <h5 class="title">Exclusion criteria</h5> <p>Patients with secondary NS were excluded.</p> </section> </section> <section id="CD008568-sec3-0003"> <h4 class="title">Types of interventions</h4> <p> <ul id="CD008568-lst1-0001"> <li> <p>Two preparations of TwHF extracts (ethanol‐ethyl acetate extract and chloroform‐methanol extract) have been investigated in clinical studies and reported to carry lower toxicity profiles compared with other TwHF preparations. This review considered only ethanol‐ethyl acetate extract and chloroform‐methanol extract of TwHF. Other TwHF preparations were excluded because of their less favourable toxicity profiles (<a href="./references#CD008568-bbs2-0076" title="TaoX , YoungerJ , FanFZ , WangB , LipskyPE . Benefit of an extract of Tripterygium Wilfordii Hook F in patients with rheumatoid arthritis: a double‐blind, placebo‐controlled study. Arthritis &amp; Rheumatism2002;46(7):1735‐43. [MEDLINE: 12124856] ">Tao 2002</a>; <a href="./references#CD008568-bbs2-0079" title="WenZH , XuWH , LaiSL . Causal relationship of adverse reactions with tripterygium in 38 patients. Zhongyao Xinyao Yu Linchuang Yaoli [Traditional Chinese Drug Research &amp; Clinical Pharmacology]1999;10(1):50‐3. ">Wen 1999</a>). </p> </li> <li> <p>TwHF versus placebo, no treatment, non‐immunosuppressive agents (such as angiotensin‐converting enzyme inhibitors, angiotensin II receptor blockers, anticoagulants, antiplatelet agents, or fish oil), or immunosuppressive drugs (glucocorticoids, alkylating agents, azathioprine, cyclosporine, tacrolimus, mycophenolate mofetil, or leflunomide). </p> </li> <li> <p>TwHF in addition to the listed immunosuppressive and non‐immunosuppressive agents versus the same drugs. Co‐interventions were permitted where all study arm patients received the same co‐interventions. </p> </li> <li> <p>Various doses, frequencies of administration, and therapeutic durations of the same TwHF preparation were included. </p> </li> <li> <p>Any preparations of other traditional Chinese herbal medicines, including single herb, compound herbs, extracts, raw materials, Chinese proprietary medicines, and practitioner‐prescribed herbal formulae (individualised treatment) according to the study report, were excluded. </p> </li> </ul> </p> </section> <section id="CD008568-sec3-0004"> <h4 class="title">Types of outcome measures</h4> <section id="CD008568-sec4-0003"> <h5 class="title">Primary outcomes</h5> <p>Complete remission, partial remission, and complete or partial remission at the last follow‐up. Complete and partial remission were assessed according to the definition provided in each single study. In the absence of an explicit definition of remission, we applied the following parameters (<a href="./references#CD008568-bbs2-0064" title="KDIGO . Idiopathic membranous nephropathy. Kidney International ‐ Supplement2012;2:186‐97. ">KDIGO 2012</a>). </p> <p> <ul id="CD008568-lst1-0002"> <li> <p>In children</p> <ul id="CD008568-lst2-0001"> <li> <p>Complete remission was defined as urine protein‐creatinine ratio &lt; 20 mg/mmol or &lt; 1+ of protein on urine dipstick for three consecutive days. </p> </li> <li> <p>Partial remission was defined as proteinuria reduction of ≥ 50% from the presenting value and absolute urine protein‐creatinine ratio of 20 to 200 mg/mmol. </p> </li> </ul> </li> </ul> <ul id="CD008568-lst1-0003"> <li> <p>In adults</p> </li> </ul> <ul class="plain" id="CD008568-lst1-0004"> <li> <ul id="CD008568-lst2-0002"> <li> <p>Complete remission was defined as proteinuria &lt; 0.3 g/24 h, accompanied by a normal serum albumin concentration and normal serum creatinine. </p> </li> <li> <p>Partial remission was defined as reduction of proteinuria to 0.3 to 3.5 g/24 h and a decrease &gt; 50% from baseline, accompanied by an improvement or normalisation of the serum albumin concentration and stable serum creatinine (change in creatinine &lt; 25%) </p> </li> </ul> </li> </ul> </p> </section> <section id="CD008568-sec4-0004"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD008568-lst1-0005"> <li> <p>Urinary protein excretion at last follow‐up</p> </li> <li> <p>Serum albumin at last follow‐up</p> </li> <li> <p>Serum creatinine at last follow‐up</p> </li> <li> <p>Adverse events of TwHF</p> </li> </ul> </p> </section> </section> </section> <section id="CD008568-sec2-0006"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD008568-sec3-0005"> <h4 class="title">Electronic searches</h4> <p> <ul id="CD008568-lst1-0006"> <li> <p>Cochrane Renal Group's specialised register were searched by the Trial Search Coordinator of Cochrane Renal Group in August 2012 </p> </li> <li> <p>Cochrane Register of Controlled Trials (CENTRAL) in <i>The Cochrane Library</i> (2012 Issue 8) </p> </li> <li> <p>PUBMED (1966 to August 2012)</p> </li> <li> <p>EMBASE (1966 to August 2012)</p> </li> <li> <p>CBM (Chinese Biological Medical Database) (1978 to November 2010)</p> </li> <li> <p>CNKI (Chinese National Knowledge Infrastructure) (1979 to November 2010)</p> </li> <li> <p>VIP (ChongQing WeiPu Chinese Science and Technology Periodical Database) (1989 to November 2010) </p> </li> <li> <p>WanFang Database (1980 to November 2010)</p> </li> </ul> </p> <p>See <a href="./appendices#CD008568-sec2-0016">Appendix 1</a> for search strategies used. </p> </section> <section id="CD008568-sec3-0006"> <h4 class="title">Searching other resources</h4> <p>We searched the reference lists of relevant studies and related Chinese journals (6 November 2010). </p> </section> </section> <section id="CD008568-sec2-0007"> <h3 class="title" id="CD008568-sec2-0007">Data collection and analysis</h3> <section id="CD008568-sec3-0007"> <h4 class="title">Selection of studies</h4> <p>The search strategy was applied to obtain titles and abstracts of relevant studies. The titles and abstracts were screened independently by two authors, who discarded studies that were not applicable; however studies and reviews that may have included relevant data or information were retained initially. Two authors independently assessed retrieved abstracts and, if necessary the full text, to determine which satisfied the inclusion criteria. Disagreements were resolved by consultation with a third author. </p> </section> <section id="CD008568-sec3-0008"> <h4 class="title">Data extraction and management</h4> <p>Data extraction was conducted independently by two authors using standard data extraction forms. Studies reported in non‐English language journals were translated before assessment. Where more than one publication of one study existed, the publication with the most complete data was included. Where relevant outcomes were published only in earlier versions, these data were included in the analyses. Any discrepancies between published versions were to be highlighted. Any further information required from the original investigators was requested by phone or written correspondence and any relevant information obtained was included in this review. Disagreements were resolved by consultation with a third author. </p> </section> <section id="CD008568-sec3-0009"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The following items were independently assessed by two authors using the risk of bias assessment tool (<a href="./references#CD008568-bbs2-0059" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). For each item, the judgement (low risk of bias, high risk of bias, or unclear risk of bias) was followed by a description of the design, conduct or observations underlying the judgement (see <a href="./appendices#CD008568-sec2-0017">Appendix 2</a>). </p> <p> <ul id="CD008568-lst1-0007"> <li> <p>Was there adequate sequence generation (selection bias)?</p> </li> <li> <p>Was allocation adequately concealed (selection bias)?</p> </li> <li> <p>Was knowledge of the allocated interventions adequately prevented during the study (detection bias)? </p> <ul id="CD008568-lst2-0003"> <li> <p>Participants and personnel</p> </li> <li> <p>Outcome assessors</p> </li> </ul> </li> <li> <p>Were incomplete outcome data adequately addressed (attrition bias)?</p> </li> <li> <p>Are reports of the study free of suggestion of selective outcome reporting (reporting bias)? </p> </li> <li> <p>Was the study apparently free of other problems that could put it at a risk of bias?</p> </li> </ul> </p> </section> <section id="CD008568-sec3-0010"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes (e.g. remission) results were expressed as risk ratios (RR) with 95% confidence intervals (CI). Where continuous scales of measurement were used to assess the effects of treatment (e.g. urinary protein excretion, serum albumin, serum creatinine), the mean difference (MD) were used, or the standardised mean difference (SMD) if different scales have been used. If possible, we also aimed to determine the applicability of the results to individual patients, such as calculation of absolute risk reductions with therapy in relation to different baseline risk of the event with no therapy or a different therapy. Adverse events were tabulated and assessed using descriptive techniques. Where possible, risk difference with 95% CI was to be calculated for each adverse event, compared with either no treatment or another agent. </p> </section> <section id="CD008568-sec3-0011"> <h4 class="title">Unit of analysis issues</h4> <p>Studies with multiple intervention arms were analysed by entering each pair‐wise comparison separately. For dichotomous outcomes, both the number of events and the total number of patients were halved. For continuous outcomes, only the total number of participants were halved, while the means and standard deviations were left unchanged (<a href="./references#CD008568-bbs2-0059" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD008568-sec3-0012"> <h4 class="title">Dealing with missing data</h4> <p>Data such as numbers of participants screened, randomised, intention‐to‐treat, and as‐treated and per‐protocol populations were evaluated and analysed. Attrition rates (drop‐outs, losses to follow‐up and withdrawals) were investigated. Issues of missing data and imputation methods (such as last‐observation‐carried‐forward) were critically appraised (<a href="./references#CD008568-bbs2-0059" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). Participant results missing due to drop‐out, intention‐to‐treat analysis was performed and compared with per‐protocol analysis for the dichotomous data; while the continuous data remained unchanged due to the difficulty of application of ITT for this type of data (<a href="./references#CD008568-bbs2-0067" title="MoherD , HopewellS , SchulzKF , MontoriV , GotzschePC , DevereauxPJ , et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ2010;340:c869. [MEDLINE: 20332511] ">Moher 2010</a>). For missing statistics such as standard deviations, these studies were not considered in the meta‐analysis unless the missing data could be appropriately imputed using methods recommended by the Cochrane Collaboration (<a href="./references#CD008568-bbs2-0059" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We also contacted principal investigators to request the missing data. </p> </section> <section id="CD008568-sec3-0013"> <h4 class="title">Assessment of heterogeneity</h4> <p>Heterogeneity was analysed using a Chi² test on N‐1 degrees of freedom, with an alpha of 0.10 used for statistical significance (<a href="./references#CD008568-bbs2-0059" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). I² values of 25%, 50% and 75% corresponded to low, medium and high levels of heterogeneity. </p> </section> <section id="CD008568-sec3-0014"> <h4 class="title">Assessment of reporting biases</h4> <p>Assessment of publication bias was not conducted because of the small numbers of included studies in the three comparisons. </p> </section> <section id="CD008568-sec3-0015"> <h4 class="title">Data synthesis</h4> <p>Data were pooled using the random‐effects model but the fixed‐effect model was also used to ensure robustness of the model chosen and susceptibility to outliers. </p> </section> <section id="CD008568-sec3-0016"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>The following subgroup analyses were planned.</p> <p> <ul id="CD008568-lst1-0008"> <li> <p>Type of NS (steroid‐resistant NS (SRNS) or frequently relapsing NS (FRNS)).</p> </li> <li> <p>NS pathology.</p> </li> <li> <p>Age of participants (e.g. children or elderly patients).</p> </li> </ul> </p> </section> <section id="CD008568-sec3-0017"> <h4 class="title">Sensitivity analysis</h4> <p> <ul id="CD008568-lst1-0009"> <li> <p>We conducted sensitivity analyses to explore the influence of diagnostic criteria of NS on the treatment effect. </p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008568-sec1-0005" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008568-sec1-0005"></div> <section id="CD008568-sec2-0008"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD008568-sec2-0020" title="">Characteristics of included studies</a> and <a href="./references#CD008568-sec2-0021" title="">Characteristics of excluded studies</a>. </p> <section id="CD008568-sec3-0018"> <h4 class="title">Results of the search</h4> <p>The search strategy identified 2938 citations (6 November 2010) (<a href="#CD008568-fig-0001">Figure 1</a>). Of these, 50 studies were considered as potentially eligible. All were conducted in China and reported in Chinese language. A total of 30/50 studies were excluded after further evaluation. We attempted to contact the investigators from the remaining 20 studies to obtain missing data. The authors of two studies could not be contacted and subsequently excluded (10%). We were successful in eliciting responses from 18 studies (90%). Eight of these studies were further excluded after contact with the investigators. </p> <div class="figure" id="CD008568-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow diagram of study selection" data-id="CD008568-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_n/nCD008568-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow diagram of study selection</p> </div> </div> </div> </section> <section id="CD008568-sec3-0019"> <h4 class="title">Included studies</h4> <p>Our review included 10 RCTs published as full reports (<a href="./references#CD008568-bbs2-0001" title="A‐DaLT , SuJH , WangZC . Clinical random control observation of 18 cases of patients with primary IgA nephropathy syndrome treated with tripterygium glycosides tablet. Dangdai Yixue [China Contemporary Medicine]2008;15(10):12‐3. ">A‐Da 2008</a>; <a href="./references#CD008568-bbs2-0002" title="ChenZM , ChenZJ . Clinical analysis of 36 cases of refractory nephrotic syndrome treated by high‐dosage Tripterygium glycosides. Zhongguo Quanke Yixue [Chinese General Practice]2003;6(11):948. ">Chen 2003</a>; <a href="./references#CD008568-bbs2-0003" title="HanJH , MouZL , WangJP . Combination of Tripterygium glycosides and cyclosporin A for the treatment of refractory nephrotic syndrome. Linchuang Huicui [Clinical Focus]1999;14(18):841‐2. ">Han 1999</a>; <a href="./references#CD008568-bbs2-0004" title="LiZ , ZhangYF , LiuF . Clinical observation of 48 cases of nephrotic syndrome treated by combined treatment of Tripterygium wilfordii and quadruple chemotherapy. Hainan Yixue [Hainan Medical Journal]1999;10(6):191‐2. LiZ , ZhangYF , LiuF . Clinical observation of 48 cases of nephrotic syndrome treated by combined treatment of Tripterygium wilfordii and quadruple chemotherapy. Yi Xue Wen Xuan [Anthology of Medicine]2000;19(2):139‐40. ">Li 2000</a>; <a href="./references#CD008568-bbs2-0005" title="SongHX , WangZT , ChenXT . Clinical study of combined treatment of cyclophosphamide and Tripterygium wilfordii for nephrotic syndrome. Lin Yi Yi Zhuan Xue Bao [Journal of Linyi Medical College]1998;20(2):109‐12. ">Song 1998</a>; <a href="./references#CD008568-bbs2-0006" title="WenYQ , ZhuQL , WangMC , RenZQ , LiuML , HuGL . Clinical therapeutic analysis of primary nephrotic syndrome treated by prednisone and Tripterygium wilfordii. Zhonghua Shenzangbing Zazhi [Chinese Journal of Nephrology]1993;9(3):190. ">Wen 1993</a>; <a href="./references#CD008568-bbs2-0007" title="YuanDS , WangYR . Clinical therapeutic analysis of primary nephrotic syndrome in elderly treated by combination treatment of Tripterygium wilfordii and medium dosage prednisone. Zhong Hua Lin Chuang Yi Xue Yan Jiu Za Zhi [Chinese Magazine of Clinical Medicinal Professional Research]2003;9(12):11475‐6. ">Yuan 2003</a>; <a href="./references#CD008568-bbs2-0008" title="ZhangF . Comparison of effects of Tripterygium glycosides plus prednisone with prednisone alone on primary nephrotic syndrome. Zhong Wai Jian Kang Wen Zhai ‐ Yi Yao Yue Kan [World Health Digest ‐ Medical Monthly]2007;4(8):96‐8. ">Zhang 2007a</a>; <a href="./references#CD008568-bbs2-0009" title="ZhaoDG , ZhaoX . Synergism of Tripterygium glycosides and prednisone for the complementary treatment of nephrotic syndrome. Changchun Zhongyiyao Daxue Xuebao [Journal of Changchun University of Traditional Chinese Medicine]1997;13(4):20‐1. ">Zhao 1997</a>; <a href="./references#CD008568-bbs2-0010" title="ZhaoL . Comparative observation of effects of Tripterygium glycosides versus cyclophosphamide for the treatment of refractory nephrotic syndrome. Hebei Yi Yao [Hebei Medical Journal]2009;31(16):2160‐1. ">Zhao 2009</a>). </p> <section id="CD008568-sec4-0005"> <h5 class="title">Baseline characteristics</h5> <p>Age and gender appeared to be balanced in all included studies. Three studies did not report if proteinuria and serum creatinine were comparable at baseline (<a href="./references#CD008568-bbs2-0004" title="LiZ , ZhangYF , LiuF . Clinical observation of 48 cases of nephrotic syndrome treated by combined treatment of Tripterygium wilfordii and quadruple chemotherapy. Hainan Yixue [Hainan Medical Journal]1999;10(6):191‐2. LiZ , ZhangYF , LiuF . Clinical observation of 48 cases of nephrotic syndrome treated by combined treatment of Tripterygium wilfordii and quadruple chemotherapy. Yi Xue Wen Xuan [Anthology of Medicine]2000;19(2):139‐40. ">Li 2000</a>; <a href="./references#CD008568-bbs2-0006" title="WenYQ , ZhuQL , WangMC , RenZQ , LiuML , HuGL . Clinical therapeutic analysis of primary nephrotic syndrome treated by prednisone and Tripterygium wilfordii. Zhonghua Shenzangbing Zazhi [Chinese Journal of Nephrology]1993;9(3):190. ">Wen 1993</a>; <a href="./references#CD008568-bbs2-0007" title="YuanDS , WangYR . Clinical therapeutic analysis of primary nephrotic syndrome in elderly treated by combination treatment of Tripterygium wilfordii and medium dosage prednisone. Zhong Hua Lin Chuang Yi Xue Yan Jiu Za Zhi [Chinese Magazine of Clinical Medicinal Professional Research]2003;9(12):11475‐6. ">Yuan 2003</a>); and seven studies reported comparability at baseline (<a href="./references#CD008568-bbs2-0001" title="A‐DaLT , SuJH , WangZC . Clinical random control observation of 18 cases of patients with primary IgA nephropathy syndrome treated with tripterygium glycosides tablet. Dangdai Yixue [China Contemporary Medicine]2008;15(10):12‐3. ">A‐Da 2008</a>; <a href="./references#CD008568-bbs2-0002" title="ChenZM , ChenZJ . Clinical analysis of 36 cases of refractory nephrotic syndrome treated by high‐dosage Tripterygium glycosides. Zhongguo Quanke Yixue [Chinese General Practice]2003;6(11):948. ">Chen 2003</a>; <a href="./references#CD008568-bbs2-0003" title="HanJH , MouZL , WangJP . Combination of Tripterygium glycosides and cyclosporin A for the treatment of refractory nephrotic syndrome. Linchuang Huicui [Clinical Focus]1999;14(18):841‐2. ">Han 1999</a>; <a href="./references#CD008568-bbs2-0005" title="SongHX , WangZT , ChenXT . Clinical study of combined treatment of cyclophosphamide and Tripterygium wilfordii for nephrotic syndrome. Lin Yi Yi Zhuan Xue Bao [Journal of Linyi Medical College]1998;20(2):109‐12. ">Song 1998</a>; <a href="./references#CD008568-bbs2-0008" title="ZhangF . Comparison of effects of Tripterygium glycosides plus prednisone with prednisone alone on primary nephrotic syndrome. Zhong Wai Jian Kang Wen Zhai ‐ Yi Yao Yue Kan [World Health Digest ‐ Medical Monthly]2007;4(8):96‐8. ">Zhang 2007a</a>; <a href="./references#CD008568-bbs2-0009" title="ZhaoDG , ZhaoX . Synergism of Tripterygium glycosides and prednisone for the complementary treatment of nephrotic syndrome. Changchun Zhongyiyao Daxue Xuebao [Journal of Changchun University of Traditional Chinese Medicine]1997;13(4):20‐1. ">Zhao 1997</a>; <a href="./references#CD008568-bbs2-0010" title="ZhaoL . Comparative observation of effects of Tripterygium glycosides versus cyclophosphamide for the treatment of refractory nephrotic syndrome. Hebei Yi Yao [Hebei Medical Journal]2009;31(16):2160‐1. ">Zhao 2009</a>). </p> </section> <section id="CD008568-sec4-0006"> <h5 class="title">Sample size</h5> <p>The 10 included studies randomised a total of 630 patients (345 in the experimental group and 285 in the control group). The median sample sizes was 64 patients (range from 36 to 92). </p> </section> <section id="CD008568-sec4-0007"> <h5 class="title">Diagnostic criteria</h5> <p>Eight studies only enrolled patients with primary NS. We contacted the investigators of the remaining two studies and confirmed that all enrolled patients had been diagnosed with primary NS (<a href="./references#CD008568-bbs2-0004" title="LiZ , ZhangYF , LiuF . Clinical observation of 48 cases of nephrotic syndrome treated by combined treatment of Tripterygium wilfordii and quadruple chemotherapy. Hainan Yixue [Hainan Medical Journal]1999;10(6):191‐2. LiZ , ZhangYF , LiuF . Clinical observation of 48 cases of nephrotic syndrome treated by combined treatment of Tripterygium wilfordii and quadruple chemotherapy. Yi Xue Wen Xuan [Anthology of Medicine]2000;19(2):139‐40. ">Li 2000</a>; <a href="./references#CD008568-bbs2-0009" title="ZhaoDG , ZhaoX . Synergism of Tripterygium glycosides and prednisone for the complementary treatment of nephrotic syndrome. Changchun Zhongyiyao Daxue Xuebao [Journal of Changchun University of Traditional Chinese Medicine]1997;13(4):20‐1. ">Zhao 1997</a>). Sensitivity analyses for diagnostic criteria were conducted to detect the potential impact of unpublished information (<a href="./references#CD008568-bbs2-0004" title="LiZ , ZhangYF , LiuF . Clinical observation of 48 cases of nephrotic syndrome treated by combined treatment of Tripterygium wilfordii and quadruple chemotherapy. Hainan Yixue [Hainan Medical Journal]1999;10(6):191‐2. LiZ , ZhangYF , LiuF . Clinical observation of 48 cases of nephrotic syndrome treated by combined treatment of Tripterygium wilfordii and quadruple chemotherapy. Yi Xue Wen Xuan [Anthology of Medicine]2000;19(2):139‐40. ">Li 2000</a>; <a href="./references#CD008568-bbs2-0009" title="ZhaoDG , ZhaoX . Synergism of Tripterygium glycosides and prednisone for the complementary treatment of nephrotic syndrome. Changchun Zhongyiyao Daxue Xuebao [Journal of Changchun University of Traditional Chinese Medicine]1997;13(4):20‐1. ">Zhao 1997</a>). </p> </section> <section id="CD008568-sec4-0008"> <h5 class="title">Age</h5> <p>Eight studies enrolled adult patients; one study included elderly patients (<a href="./references#CD008568-bbs2-0007" title="YuanDS , WangYR . Clinical therapeutic analysis of primary nephrotic syndrome in elderly treated by combination treatment of Tripterygium wilfordii and medium dosage prednisone. Zhong Hua Lin Chuang Yi Xue Yan Jiu Za Zhi [Chinese Magazine of Clinical Medicinal Professional Research]2003;9(12):11475‐6. ">Yuan 2003</a>); and one enrolled both adults and children (<a href="./references#CD008568-bbs2-0004" title="LiZ , ZhangYF , LiuF . Clinical observation of 48 cases of nephrotic syndrome treated by combined treatment of Tripterygium wilfordii and quadruple chemotherapy. Hainan Yixue [Hainan Medical Journal]1999;10(6):191‐2. LiZ , ZhangYF , LiuF . Clinical observation of 48 cases of nephrotic syndrome treated by combined treatment of Tripterygium wilfordii and quadruple chemotherapy. Yi Xue Wen Xuan [Anthology of Medicine]2000;19(2):139‐40. ">Li 2000</a>). </p> </section> <section id="CD008568-sec4-0009"> <h5 class="title">Clinical conditions</h5> <p>Four studies included patients with primary refractory NS (<a href="./references#CD008568-bbs2-0002" title="ChenZM , ChenZJ . Clinical analysis of 36 cases of refractory nephrotic syndrome treated by high‐dosage Tripterygium glycosides. Zhongguo Quanke Yixue [Chinese General Practice]2003;6(11):948. ">Chen 2003</a>; <a href="./references#CD008568-bbs2-0003" title="HanJH , MouZL , WangJP . Combination of Tripterygium glycosides and cyclosporin A for the treatment of refractory nephrotic syndrome. Linchuang Huicui [Clinical Focus]1999;14(18):841‐2. ">Han 1999</a>; <a href="./references#CD008568-bbs2-0005" title="SongHX , WangZT , ChenXT . Clinical study of combined treatment of cyclophosphamide and Tripterygium wilfordii for nephrotic syndrome. Lin Yi Yi Zhuan Xue Bao [Journal of Linyi Medical College]1998;20(2):109‐12. ">Song 1998</a>; <a href="./references#CD008568-bbs2-0010" title="ZhaoL . Comparative observation of effects of Tripterygium glycosides versus cyclophosphamide for the treatment of refractory nephrotic syndrome. Hebei Yi Yao [Hebei Medical Journal]2009;31(16):2160‐1. ">Zhao 2009</a>). The remaining six studies included patients with primary NS. </p> </section> <section id="CD008568-sec4-0010"> <h5 class="title">Pathologic conditions</h5> <p>Common pathologic diagnoses reported in nine included studies were MCN, FSGS, MsPGN (including IgA nephropathy), MN, and MPGN. One study included only adults with primary IgA nephropathy‐induced primary NS (<a href="./references#CD008568-bbs2-0001" title="A‐DaLT , SuJH , WangZC . Clinical random control observation of 18 cases of patients with primary IgA nephropathy syndrome treated with tripterygium glycosides tablet. Dangdai Yixue [China Contemporary Medicine]2008;15(10):12‐3. ">A‐Da 2008</a>). </p> </section> <section id="CD008568-sec4-0011"> <h5 class="title">TwHF treatment</h5> <p>Initial doses of TwHF ranged from 0.5 mg/kg/d (<a href="./references#CD008568-bbs2-0006" title="WenYQ , ZhuQL , WangMC , RenZQ , LiuML , HuGL . Clinical therapeutic analysis of primary nephrotic syndrome treated by prednisone and Tripterygium wilfordii. Zhonghua Shenzangbing Zazhi [Chinese Journal of Nephrology]1993;9(3):190. ">Wen 1993</a>) to 2.0 mg/kg/d (<a href="./references#CD008568-bbs2-0005" title="SongHX , WangZT , ChenXT . Clinical study of combined treatment of cyclophosphamide and Tripterygium wilfordii for nephrotic syndrome. Lin Yi Yi Zhuan Xue Bao [Journal of Linyi Medical College]1998;20(2):109‐12. ">Song 1998</a>; <a href="./references#CD008568-bbs2-0010" title="ZhaoL . Comparative observation of effects of Tripterygium glycosides versus cyclophosphamide for the treatment of refractory nephrotic syndrome. Hebei Yi Yao [Hebei Medical Journal]2009;31(16):2160‐1. ">Zhao 2009</a>), and were administered for four (<a href="./references#CD008568-bbs2-0002" title="ChenZM , ChenZJ . Clinical analysis of 36 cases of refractory nephrotic syndrome treated by high‐dosage Tripterygium glycosides. Zhongguo Quanke Yixue [Chinese General Practice]2003;6(11):948. ">Chen 2003</a>; <a href="./references#CD008568-bbs2-0010" title="ZhaoL . Comparative observation of effects of Tripterygium glycosides versus cyclophosphamide for the treatment of refractory nephrotic syndrome. Hebei Yi Yao [Hebei Medical Journal]2009;31(16):2160‐1. ">Zhao 2009</a>) and eight weeks (<a href="./references#CD008568-bbs2-0001" title="A‐DaLT , SuJH , WangZC . Clinical random control observation of 18 cases of patients with primary IgA nephropathy syndrome treated with tripterygium glycosides tablet. Dangdai Yixue [China Contemporary Medicine]2008;15(10):12‐3. ">A‐Da 2008</a>; <a href="./references#CD008568-bbs2-0005" title="SongHX , WangZT , ChenXT . Clinical study of combined treatment of cyclophosphamide and Tripterygium wilfordii for nephrotic syndrome. Lin Yi Yi Zhuan Xue Bao [Journal of Linyi Medical College]1998;20(2):109‐12. ">Song 1998</a>; <a href="./references#CD008568-bbs2-0009" title="ZhaoDG , ZhaoX . Synergism of Tripterygium glycosides and prednisone for the complementary treatment of nephrotic syndrome. Changchun Zhongyiyao Daxue Xuebao [Journal of Changchun University of Traditional Chinese Medicine]1997;13(4):20‐1. ">Zhao 1997</a>). </p> </section> <section id="CD008568-sec4-0012"> <h5 class="title">Follow‐up</h5> <p>The median follow‐up was 12 months (range: 3 to 18 months).</p> </section> <section id="CD008568-sec4-0013"> <h5 class="title">Comparisons</h5> <p>A presentation of comparisons in these 10 included studies was presented in additional <a href="#CD008568-tbl-0007">Table 1</a>. Nine studies featured two‐arm design. <a href="./references#CD008568-bbs2-0009" title="ZhaoDG , ZhaoX . Synergism of Tripterygium glycosides and prednisone for the complementary treatment of nephrotic syndrome. Changchun Zhongyiyao Daxue Xuebao [Journal of Changchun University of Traditional Chinese Medicine]1997;13(4):20‐1. ">Zhao 1997</a> conducted a three‐armed study that compared 34 patients receiving TwHF plus prednisone (0.6 mg/kg/d), 26 patients receiving TwHF, and 26 patients receiving prednisone (1.0 mg/kg/d). The prednisone group (1.0 mg/kg/d) was split into two equal‐sized subgroups. Two comparisons were conducted: (A) TwHF plus prednisone (0.6 mg/kg/d) (N = 34) versus prednisone (1.0 mg/kg/d) (N = 13) and (B) TwHF (N = 26) versus prednisone (1.0 mg/kg/d) (N = 13). We conducted primary analyses according to experimental and control interventions: </p> <div class="table" id="CD008568-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Study treatment, control and comparison groups</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>follow‐up (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Co‐interventions</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b> TwHF versus non‐TwHF</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008568-bbs2-0004" title="LiZ , ZhangYF , LiuF . Clinical observation of 48 cases of nephrotic syndrome treated by combined treatment of Tripterygium wilfordii and quadruple chemotherapy. Hainan Yixue [Hainan Medical Journal]1999;10(6):191‐2. LiZ , ZhangYF , LiuF . Clinical observation of 48 cases of nephrotic syndrome treated by combined treatment of Tripterygium wilfordii and quadruple chemotherapy. Yi Xue Wen Xuan [Anthology of Medicine]2000;19(2):139‐40. ">Li 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TwHF + prednisone + CPA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prednisone + CPA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same co‐interventions and doses in each arm</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008568-bbs2-0005" title="SongHX , WangZT , ChenXT . Clinical study of combined treatment of cyclophosphamide and Tripterygium wilfordii for nephrotic syndrome. Lin Yi Yi Zhuan Xue Bao [Journal of Linyi Medical College]1998;20(2):109‐12. ">Song 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TwHF + prednisone + CPA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prednisone + CPA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12‐15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same co‐interventions and doses in each arm</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008568-bbs2-0006" title="WenYQ , ZhuQL , WangMC , RenZQ , LiuML , HuGL . Clinical therapeutic analysis of primary nephrotic syndrome treated by prednisone and Tripterygium wilfordii. Zhonghua Shenzangbing Zazhi [Chinese Journal of Nephrology]1993;9(3):190. ">Wen 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TwHF + prednisone (1.0 mg/kg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prednisone (1.0 mg/kg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12‐16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same co‐interventions and doses in each arm</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008568-bbs2-0008" title="ZhangF . Comparison of effects of Tripterygium glycosides plus prednisone with prednisone alone on primary nephrotic syndrome. Zhong Wai Jian Kang Wen Zhai ‐ Yi Yao Yue Kan [World Health Digest ‐ Medical Monthly]2007;4(8):96‐8. ">Zhang 2007a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TwHF + prednisone (1.0 mg/kg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prednisone (1.0 mg/kg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same co‐interventions and doses in each arm</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b> TwHF versus prednisone</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008568-bbs2-0001" title="A‐DaLT , SuJH , WangZC . Clinical random control observation of 18 cases of patients with primary IgA nephropathy syndrome treated with tripterygium glycosides tablet. Dangdai Yixue [China Contemporary Medicine]2008;15(10):12‐3. ">A‐Da 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TwHF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prednisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same co‐interventions and doses in each arm</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008568-bbs2-0003" title="HanJH , MouZL , WangJP . Combination of Tripterygium glycosides and cyclosporin A for the treatment of refractory nephrotic syndrome. Linchuang Huicui [Clinical Focus]1999;14(18):841‐2. ">Han 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TwHF + CSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prednisone + CSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same co‐interventions and doses in each arm</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008568-bbs2-0007" title="YuanDS , WangYR . Clinical therapeutic analysis of primary nephrotic syndrome in elderly treated by combination treatment of Tripterygium wilfordii and medium dosage prednisone. Zhong Hua Lin Chuang Yi Xue Yan Jiu Za Zhi [Chinese Magazine of Clinical Medicinal Professional Research]2003;9(12):11475‐6. ">Yuan 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TwHF + prednisone (0.4 to 0.5 mg/kg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prednisone (0.8 to 1.0 mg/kg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12‐18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same co‐interventions and doses in each arm</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008568-bbs2-0009" title="ZhaoDG , ZhaoX . Synergism of Tripterygium glycosides and prednisone for the complementary treatment of nephrotic syndrome. Changchun Zhongyiyao Daxue Xuebao [Journal of Changchun University of Traditional Chinese Medicine]1997;13(4):20‐1. ">Zhao 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TwHF + prednisone (0.6 mg/kg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prednisone (1.0 mg/kg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10‐12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same co‐interventions and doses in each arm</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008568-bbs2-0009" title="ZhaoDG , ZhaoX . Synergism of Tripterygium glycosides and prednisone for the complementary treatment of nephrotic syndrome. Changchun Zhongyiyao Daxue Xuebao [Journal of Changchun University of Traditional Chinese Medicine]1997;13(4):20‐1. ">Zhao 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TwHF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prednisone (1.0 mg/kg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10‐12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same co‐interventions and doses in each arm</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b> TwHF versus CPA</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008568-bbs2-0002" title="ChenZM , ChenZJ . Clinical analysis of 36 cases of refractory nephrotic syndrome treated by high‐dosage Tripterygium glycosides. Zhongguo Quanke Yixue [Chinese General Practice]2003;6(11):948. ">Chen 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TwHF + prednisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CPA + prednisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same co‐interventions and doses in each arm</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008568-bbs2-0010" title="ZhaoL . Comparative observation of effects of Tripterygium glycosides versus cyclophosphamide for the treatment of refractory nephrotic syndrome. Hebei Yi Yao [Hebei Medical Journal]2009;31(16):2160‐1. ">Zhao 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TwHF + prednisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CPA + prednisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same co‐interventions and doses in each arm</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CPA: cyclophosphamide; CSA: cyclosporine; TwHF: <i>Tripterygium wilfordii</i> Hook F </p> </div> </div> <p> <ul id="CD008568-lst1-0010"> <li> <p>TwHF versus non‐TwHF (<a href="./references#CD008568-bbs2-0004" title="LiZ , ZhangYF , LiuF . Clinical observation of 48 cases of nephrotic syndrome treated by combined treatment of Tripterygium wilfordii and quadruple chemotherapy. Hainan Yixue [Hainan Medical Journal]1999;10(6):191‐2. LiZ , ZhangYF , LiuF . Clinical observation of 48 cases of nephrotic syndrome treated by combined treatment of Tripterygium wilfordii and quadruple chemotherapy. Yi Xue Wen Xuan [Anthology of Medicine]2000;19(2):139‐40. ">Li 2000</a>; <a href="./references#CD008568-bbs2-0005" title="SongHX , WangZT , ChenXT . Clinical study of combined treatment of cyclophosphamide and Tripterygium wilfordii for nephrotic syndrome. Lin Yi Yi Zhuan Xue Bao [Journal of Linyi Medical College]1998;20(2):109‐12. ">Song 1998</a>; <a href="./references#CD008568-bbs2-0006" title="WenYQ , ZhuQL , WangMC , RenZQ , LiuML , HuGL . Clinical therapeutic analysis of primary nephrotic syndrome treated by prednisone and Tripterygium wilfordii. Zhonghua Shenzangbing Zazhi [Chinese Journal of Nephrology]1993;9(3):190. ">Wen 1993</a>; <a href="./references#CD008568-bbs2-0008" title="ZhangF . Comparison of effects of Tripterygium glycosides plus prednisone with prednisone alone on primary nephrotic syndrome. Zhong Wai Jian Kang Wen Zhai ‐ Yi Yao Yue Kan [World Health Digest ‐ Medical Monthly]2007;4(8):96‐8. ">Zhang 2007a</a>). </p> </li> <li> <p>TwHF versus prednisone (<a href="./references#CD008568-bbs2-0001" title="A‐DaLT , SuJH , WangZC . Clinical random control observation of 18 cases of patients with primary IgA nephropathy syndrome treated with tripterygium glycosides tablet. Dangdai Yixue [China Contemporary Medicine]2008;15(10):12‐3. ">A‐Da 2008</a>; <a href="./references#CD008568-bbs2-0003" title="HanJH , MouZL , WangJP . Combination of Tripterygium glycosides and cyclosporin A for the treatment of refractory nephrotic syndrome. Linchuang Huicui [Clinical Focus]1999;14(18):841‐2. ">Han 1999</a>; <a href="./references#CD008568-bbs2-0007" title="YuanDS , WangYR . Clinical therapeutic analysis of primary nephrotic syndrome in elderly treated by combination treatment of Tripterygium wilfordii and medium dosage prednisone. Zhong Hua Lin Chuang Yi Xue Yan Jiu Za Zhi [Chinese Magazine of Clinical Medicinal Professional Research]2003;9(12):11475‐6. ">Yuan 2003</a>; <a href="./references#CD008568-bbs2-0009" title="ZhaoDG , ZhaoX . Synergism of Tripterygium glycosides and prednisone for the complementary treatment of nephrotic syndrome. Changchun Zhongyiyao Daxue Xuebao [Journal of Changchun University of Traditional Chinese Medicine]1997;13(4):20‐1. ">Zhao 1997</a>). </p> </li> <li> <p>TwHF versus CPA (<a href="./references#CD008568-bbs2-0002" title="ChenZM , ChenZJ . Clinical analysis of 36 cases of refractory nephrotic syndrome treated by high‐dosage Tripterygium glycosides. Zhongguo Quanke Yixue [Chinese General Practice]2003;6(11):948. ">Chen 2003</a>; <a href="./references#CD008568-bbs2-0010" title="ZhaoL . Comparative observation of effects of Tripterygium glycosides versus cyclophosphamide for the treatment of refractory nephrotic syndrome. Hebei Yi Yao [Hebei Medical Journal]2009;31(16):2160‐1. ">Zhao 2009</a>). </p> </li> </ul> </p> </section> </section> <section id="CD008568-sec3-0020"> <h4 class="title">Excluded studies</h4> <p>We excluded 40 studies from this review.</p> <p> <ul id="CD008568-lst1-0011"> <li> <p>Thirteen studies were not randomised (<a href="./references#CD008568-bbs2-0013" title="HanSL , LiGX , ZhouLH , HuangS , LingYS . Clinical therapeutic observation of prednisone plus Tripterygium glycosides in the treatment of nephrotic syndrome (type I). Zhongguo Zhongxiyi Jiehe Shenbing Zazhi [Chinese Journal of Integrated Traditional and Western Nephrology]2001;2(2):115‐6. ">Han 2001</a>; <a href="./references#CD008568-bbs2-0014" title="HuGH , YiZW , WangJH , YaoJC . Effect of triptergium wilfordii polyglycosidium on content of Th1 and Th2 in child recurrent nephrotic syndrome. Zhongguo Zhongyao Zazhi [China Journal of Chinese Materia Medica]2008; Vol. 33, issue 4:441‐3. [CN‐00716138] ">Hu 2008</a>; <a href="./references#CD008568-bbs2-0020" title="LiuZH , YuanF , WangYF . Tripterygium wilfordii combined with prednisone in the treatment of refractory primary nephrotic syndrome. Zhong Guo Yi Xue Chuang Xin [Medical Innovation of China]2010;7(3):1‐2. ">Liu 2010</a>; <a href="./references#CD008568-bbs2-0021" title="LuXT . Combined Tripterygium wilfordii and prednisone for the treatment of nephrotic syndrome. Xiandai Zhongxiyijiehe Zazhi [Modern Journal of Integrated Traditional Chinese and Western Medicine]2003;12(10):1058. ">Lu 2003</a>; <a href="./references#CD008568-bbs2-0022" title="MaP . Effect of Tripterygium wilfordii combined with small‐dosage prednisone on nephrosis syndrome. Linchuang Huicui [Clinical Focus]1991;6(5):210‐1. ">Ma 1991</a>; <a href="./references#CD008568-bbs2-0024" title="PangW , FuHF , TangDS . Clinical observation of integrated traditional Chinese and western medicine in treatment of nephrotic syndrome. Guangzhou Yixueyuan Xuebao [Academic Journal of Guangzhou Medical College]1999;27(3):43‐5. ">Pang 1999</a>; <a href="./references#CD008568-bbs2-0029" title="WangHW , ChenJH . Comparison of effects of Tripterygium wilfordii and prednisone in treatment of nephrotic syndrome in elderly. Youjiang Minzu Yixueyuan Xuebao [Journal of Youjiang Medical College for Nationalities]2000;22(6):883‐4. ">Wang 2000</a>; <a href="./references#CD008568-bbs2-0033" title="WangKM , LaiXH , XuRF . Tripterygium wilfordii for the treatment of refractory primary nephrotic syndrome. Zhongguo Zhongxiyi Jiehe Zazhi [Chinese Journal of Integrated Traditional and Western Medicine]2005;15(6):341‐2. ">Wang 2005b</a>; <a href="./references#CD008568-bbs2-0028" title="WangKL , WangDM . Effects of combination of prednisone and Tripterygium wilfordii in 30 patients with primary nephrotic syndrome. Da Li Yi Xue Yuan Xue Bao [Journal of Dali Medical College]1996;5(4):36‐7. ">Wang 1996</a>; <a href="./references#CD008568-bbs2-0036" title="XiaoHQ , DingGH , ZhangJE , ZhangQH , LiT , LuoCX . Comparison between the therapeutic effects of Tripterygium wilfordii and cyclophosphamide on primary nephrotic syndrome. Linchuang Huicui [Clinical Focus]2003;18(18):1039‐40. XiaoHQ , ZhangJE , YeCY . Effects of Tripterygium wilfordii on primary nephrotic syndrome. Lin Chuang Shen Zang Bing Za Zhi [Journal of Clinical Nephrology]2001;1(3):131‐3. ">Xiao 2003</a>; <a href="./references#CD008568-bbs2-0039" title="XuYZ , HuangZQ , TangR . Effect of Tripterygium wilfordii together with prednisone in treatment of elderly primary nephrotic syndrome. Zhongguo Jiceng Yiyao [Chinese Journal of Primary Medicine and Pharmacy]2009;16(5):781‐2. ">Xu 2009b</a>; <a href="./references#CD008568-bbs2-0042" title="YangJ , FanLH . Therapeutic observation of Tripterygium wilfordii and prednisone in the treatment of primary nephrotic syndrome. Zhong Guo Shi Yong Yi Yao [China Practical Medical]2010;5(16):161‐2. ">Yang 2010</a>; <a href="./references#CD008568-bbs2-0048" title="ZhongZH , LuJJ , CaiCD . Clinical analysis of 30 patients with refractory nephrotic syndrome treated by prednisone and Tripterygium wilfordii. Zhong Guo Zong He Lin Chuang [Clinical Medicine of China]2002;18(5):435‐6. ">Zhong 2002</a>). </p> </li> <li> <p>Four included patients with secondary NS (<a href="./references#CD008568-bbs2-0019" title="LiuCM , LiuY , XuK . Clinical therapeutic observation of Tripterygium glycosides for the treatment of nephrotic syndrome. Guizhou Yiyao [Guizhou Medical Journal]2003;27(5):442‐4. ">Liu 2003b</a>; <a href="./references#CD008568-bbs2-0031" title="WangLN , TangXZ , ChenPP . Clinical therapeutic observation of prednisone plus Tripterygium wilfordii for the treatment of nephrotic syndrome. Zhongguo Zhongxiyi Jiehe Shenbing Zazhi [Chinese Journal of Integrated Traditional and Western Nephrology]2002;3(7):418‐9. ">Wang 2002</a>; <a href="./references#CD008568-bbs2-0044" title="ZhaiXS , ZhouTG , ZouY , ChenT . Clinical therapeutic analysis of 32 patients with nephrotic syndrome treated by Tripterygium wilfordii and prednisone. Xian Dai Yi Yao Wei Sheng [Modern Medicine Health]2004;20(21):2246‐7. ">Zhai 2004</a>; <a href="./references#CD008568-bbs2-0046" title="ZhangX , HeXM , DuWB , ZhaoCL . Effect of Tripterygium wilfordii combined with moiety prednisone on treatment of the aged nephrosis syndrome. Zhongguo Jiceng Yiyao [Chinese Journal of Primary Medicine and Pharmacy]2010;17(5):623‐5. ">Zhang 2010</a>). </p> </li> <li> <p>Non‐standardised preparations of TwHF were investigated in two studies (<a href="./references#CD008568-bbs2-0015" title="HuangGH . Therapeutic effect analysis of Tripterygium wilfordii on the treatment of chronic nephrosis. Shiyong Linchuang Yixue [Practical Clinical Medicine]2003;4(2):48. ">Huang 2003</a>; <a href="./references#CD008568-bbs2-0047" title="ZhengDH , SuP , FangJY , WeiHM . Clinical therapeutic observation of 26 patients with nephrotic syndrome treated by Tripterygium wilfordii and urokinase. Huazhong Yixue Zazhi [Central China Medical Journal]1987;11(2):77‐8. ">Zheng 1987</a>). </p> </li> <li> <p>Six studies were excluded because the co‐interventions were not balanced between treatment group and control group (<a href="./references#CD008568-bbs2-0023" title="MoXX . Effect of Tripterygium wilfordii combined with leflunomide on refractory nephrosis syndrome. Zhongguo Shequ Yishi [Chinese Community Doctors]2009;11(10):54‐5. ">Mo 2009</a>; <a href="./references#CD008568-bbs2-0027" title="TangXL , HongSJ , TangLL . Clinical therapeutic observation of combined Tripterygium wilfordii and ticlopidine in treatment of refractory nephrotic syndrome. Zhongguo Zhongxiyi Jiehe Shenbing Zazhi [Chinese Journal of Integrated Traditional and Western Nephrology]2004;5(1):27. ">Tang 2004</a>; <a href="./references#CD008568-bbs2-0035" title="WenJF , CaoJX . Observation of effects of Tripterygium wilfordii and heparin on nephrotic syndrome. Zhongguo Xiandai Yixue Zazhi [China Journal of Modern Medicine]1996;6(2):42. ">Wen 1996</a>; <a href="./references#CD008568-bbs2-0040" title="YangXH , YuRF . Therapeutic observation of 40 patients with primary nephrotic syndrome and infection. Shiyong Yixue Zazhi [Journal of Practical Medicine]1995;11(11):725‐6. ">Yang 1995</a>; <a href="./references#CD008568-bbs2-0041" title="YangLR . Combination of Tripterygium wilfordii and levamisole for the treatment of 41 patients with nephrotic syndrome. He Nan Yi Yao Xin Xi [Henan Medical Information]2002;10(14):58‐9. ">Yang 2002</a>; <a href="./references#CD008568-bbs2-0043" title="YeYJ . Therapeutic observation of effect of combined leflunomide and tripterygium on refractory nephrotic syndrome. Jilin Yixue [Jilin Medical Journal]2010;31(6):773. ">Ye 2010</a>). </p> </li> <li> <p>Ten studies were excluded because other traditional Chinese herbal medicines were compared (<a href="./references#CD008568-bbs2-0011" title="ChangH , LiHP . Clinical analysis of 52 patients with nephrotic syndrome treated by Tripterygium glycosides and Fu Fang Dan Shen (active ingredients were Radix Salviae Miltiorrhizae and Lignum Dallbergiae Odoriferae). Zhong Guo Lin Chuang Yi Yao Yan Jiu Za Zhi [Chinese Journal of Clinical Medicine Research]2005;11(4):14919‐20. ">Chang 2005</a>; <a href="./references#CD008568-bbs2-0012" title="DuXY . Clinical observation of effects of combined treatment for 50 patients with nephrotic syndrome. Zhong Guo Xian Dai Yao Wu Ying Yong [Chinese Journal of Modern Drug Application]2008;2(11):98‐9. ">Du 2008</a>; <a href="./references#CD008568-bbs2-0004" title="LiZ , ZhangYF , LiuF . Clinical observation of 48 cases of nephrotic syndrome treated by combined treatment of Tripterygium wilfordii and quadruple chemotherapy. Hainan Yixue [Hainan Medical Journal]1999;10(6):191‐2. LiZ , ZhangYF , LiuF . Clinical observation of 48 cases of nephrotic syndrome treated by combined treatment of Tripterygium wilfordii and quadruple chemotherapy. Yi Xue Wen Xuan [Anthology of Medicine]2000;19(2):139‐40. ">Li 2000</a>; <a href="./references#CD008568-bbs2-0026" title="SunXH , LiHJ , HanW , LiBH . Observation on the therapeutic effect of the prednisone, Tripterygium wilfordii, ligustrazin in old age primary nephrotic syndrome. Xin Jiang Yi Ke Da Xue Xue Bao [Journal of Xinjiang Medical University]2008;31(6):676‐8. ">Sun 2008</a>; <a href="./references#CD008568-bbs2-0030" title="WangQY , ZhaoXH , ZhouWY , WangXY . Clinical study of combined Tripterygium wilfordii and Shu Xue Tong injection in treatment of refractory nephrosis in adults. Zhongguo Zhongxiyi Jiehe Shenbing Zazhi [Chinese Journal of Integrated Traditional and Western Nephrology]2001;2(10):606‐7. WangQY , ZhouWY , ZhaoXH . Clinical study of combined Tripterygium wilfordii and Shu Xue Tong injection in treatment of refractory nephrosis in adults. Heilongjiang Yi Xue [Heilongjiang Medical Journal]2001;14(3):212. ">Wang 2001</a>; <a href="./references#CD008568-bbs2-0032" title="WangDY . Clinical therapeutic observation of combined Tripterygium wilfordii and lumbrokinase in the adjunctive treatment of primary nephrotic syndrome. Jiangxi Yiyao [Jiangxi Medical Journal]2005;40(Suppl):694‐6. ">Wang 2005a</a>; <a href="./references#CD008568-bbs2-0034" title="WangYL . Clinical observation of integrated traditional Chinese and western medicine in treatment of nephrotic syndrome. Zhongyuan Yikan [Central Plains Medical Journal]2006;33(10):60‐1. ">Wang 2006</a>; <a href="./references#CD008568-bbs2-0038" title="XuZH , HouCA , ChenY , XueQZ . Clinical observation of integrated traditional Chinese and western medicine in treatment of nephrotic syndrome. Shi Yong Zhong Xi Yi Jie He Za Zhi [The Practical Journal of Integrating Chinese with Modern Medicine]1998;11(1):62. ">Xu 1998</a>; <a href="./references#CD008568-bbs2-0045" title="ZhangCF , WangZ , WangML , HuaMN . Therapeutic analysis of 70 patients with nephrotic syndrome. Zhong Guo Shi Yong Yi Yao [China Practical Medical]2007;2(36):137‐8. ">Zhang 2007b</a>; <a href="./references#CD008568-bbs2-0050" title="ZhouYZ . Clinical therapeutic observation of integrated traditional Chinese and western medicine in treatment of primary nephrotic syndrome. Hebei Zhongyi [Hebei Journal of Traditional Chinese Medicine]2000;22(8):620‐1. ">Zhou 2000</a>). </p> </li> <li> <p>None of our primary outcomes were reported in two studies (<a href="./references#CD008568-bbs2-0017" title="LinX , YangFF , YouYW , ChenLX , WangJ , LiSL . Clinical efficacy of double dosage of Tripterygium wilfordii with intermittent maintenance therapy in treatment of primary nephrotic syndrome. Youjiang Minzu Yixueyuan Xuebao [Journal of Youjiang Medical College for Nationalities]2005;27(3):282‐4. ">Lin 2005</a>; <a href="./references#CD008568-bbs2-0018" title="LiuAM , WangYP , DaiYW , YangC , TangHY . Clinical observation of the re‐treatment after relapse in children with primary nephrotic syndrome. Zhejiang Zhongyi Zazhi [Zhejiang Journal of Traditional Chinese Medicine]2003;38(3):334. ">Liu 2003a</a>). </p> </li> <li> <p>One study was only followed for two months (<a href="./references#CD008568-bbs2-0037" title="XiaoYC . Clinical therapeutic observation of 56 patients with primary nephrotic syndrome treated by Tripterygium wilfordii. Shi Yong Quan Ke Yi Xue [Applied Journal of General Practice]2007;5(4):312‐3. ">Xiao 2007</a>). </p> </li> <li> <p>Two studies were excluded because the investigators could not be contacted for the information about randomisation (<a href="./references#CD008568-bbs2-0025" title="SongB . Comparison between the therapeutic effects of cyclophosphamide and Tripterygium wilfordii hook on children refractory nephrotic syndrome. Zhong Guo Shi Yong Yi Yao [China Practical Medicine]2008;3(14):7‐8. ">Song 2008</a>; <a href="./references#CD008568-bbs2-0049" title="ZhouYC . Tripterygium wilfordii in combination with small‐dosage prednisone for the treatment of nephrotic syndrome. Hebei Yixue [Hebei Medicine]1999;5(4):14‐6. ">Zhou 1999</a>). </p> </li> </ul> </p> </section> </section> <section id="CD008568-sec2-0009"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD008568-fig-0002">Figure 2</a> and <a href="#CD008568-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD008568-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD008568-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_n/nCD008568-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD008568-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD008568-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_n/nCD008568-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <section id="CD008568-sec3-0021"> <h4 class="title">Allocation</h4> <section id="CD008568-sec4-0014"> <h5 class="title">Sequence generation</h5> <p>Although all included studies were RCTs, explicit methods of randomised sequence generation was described in only one. <a href="./references#CD008568-bbs2-0001" title="A‐DaLT , SuJH , WangZC . Clinical random control observation of 18 cases of patients with primary IgA nephropathy syndrome treated with tripterygium glycosides tablet. Dangdai Yixue [China Contemporary Medicine]2008;15(10):12‐3. ">A‐Da 2008</a> used a random number table for sequencing. We determined that drawing of lots was used in nine studies by contacting study investigators. </p> </section> <section id="CD008568-sec4-0015"> <h5 class="title">Allocation concealment</h5> <p>None of the included studies described allocation sequence concealment methods after contact with study investigators. </p> </section> </section> <section id="CD008568-sec3-0022"> <h4 class="title">Blinding</h4> <p>None of the included studies reported blinding methods.</p> </section> <section id="CD008568-sec3-0023"> <h4 class="title">Incomplete outcome data</h4> <p>None of the studies described losses to follow‐up or treatment withdrawals.</p> </section> <section id="CD008568-sec3-0024"> <h4 class="title">Selective reporting</h4> <p>The primary outcome (remission) was reported in all included studies. Secondary outcome data on urinary protein excretion, serum albumin, serum creatinine, and drug‐related adverse events were presented in two (20%), two (20%), three (30%), and five studies (50%), respectively. </p> </section> <section id="CD008568-sec3-0025"> <h4 class="title">Other potential sources of bias</h4> <p>There was insufficient information to determine other potential sources of bias.</p> </section> </section> <section id="CD008568-sec2-0010"> <h3 class="title" id="CD008568-sec2-0010">Effects of interventions</h3> <p>See: <a href="./full#CD008568-tbl-0001"><b>Summary of findings for the main comparison</b> Summary of findings: <i>Tripterygium wilfordii</i> Hook F (TwHF) versus no TwHF</a>; <a href="./full#CD008568-tbl-0002"><b>Summary of findings 2</b> Summary of findings: <i>Tripterygium wilfordii</i> Hook F versus prednisone</a>; <a href="./full#CD008568-tbl-0003"><b>Summary of findings 3</b> Summary of findings: Comparison of TwHF and CPA</a> </p> <p>Results are presented in <a href="./full#CD008568-tbl-0001">summary of findings Table for the main comparison</a>, <a href="./full#CD008568-tbl-0002">summary of findings Table 2</a> and <a href="./full#CD008568-tbl-0003">summary of findings Table 3</a>. Subgroup and sensitivity analyses are presented in <a href="#CD008568-tbl-0008">Table 2</a> (TwHF versus non‐TwHF) and <a href="#CD008568-tbl-0009">Table 3</a> (TwHF versus prednisone). </p> <div class="table" id="CD008568-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Subgroup and sensitivity analyses comparing Tripterygium wilfordii Hook F (TwHF) with no TwHF</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome or subgroup</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Studies (participants)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Statistical method</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Effect estimate (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Heterogeneity</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Subgroup difference</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR (TwHF versus no TwHF for non‐FRNS)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (235)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.004, RR = 1.41 (1.11 to 1.79)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.33, I² = 10%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>P = 0.37, I² = 0%</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR (TwHF versus no TwHF for FRNS)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1(58)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.03, RR = 1.87 (1.07 to 3.26)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PR (TwHF versus no TWHF for non‐FRNS)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (235)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.39, RR = 0.80 (0.48 to 1.33)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.79, I² = 0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>P = 0.81, I² = 0%</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PR (TwHF versus no TwHF for FRNS)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (58)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.45, RR = 0.70 (0.28 to 1.76)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR+PR (TwHF versus no TwHF for non‐FRNS)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (235)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.005, RR = 1.24 (1.07 to 1.43)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.64, I² = 0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>P = 0.62, I² = 0%</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR+PR (TwHF versus no TwHF for FRNS)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (58)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.06, RR = 1.35 (0.99 to 1.84)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR (TwHF + prednisone versus prednisone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (143)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.14, RR = 1.43 (0.86 to 2.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.19, I² = 42%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>P = 0.62, I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR (TwHF + prednisone + CPA versus prednisone + CPA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (150)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.002, RR = 1.65 (1.21 to 2.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.60, I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PR (TwHF + prednisone versus prednisone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (143)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.72, RR = 0.89 (0.47 to 1.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.73, I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>P = 0.53, I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PR (TwHF + prednisone + CPA versus prednisone + CPA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (150)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.21, RR = 0.67 (0.35 to 1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.89, I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR+PR (TwHF + prednisone versus prednisone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (143)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.04, RR = 1.22 (1.01 to 1.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.35, I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>P = 0.72, I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR+PR (TwHF + prednisone + CPA versus prednisone + CPA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (150)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.008, RR = 1.29 (1.07 to 1.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.71, I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR (sensitivity analysis for diagnostic criteria)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (201)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.02, RR = 1.50 (1.07 to 2.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.23, I² = 31%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> ‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PR (sensitivity analysis for diagnostic criteria)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (201)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.47, RR = 0.83 (0.49 to 1.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.86, I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> ‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR+PR (sensitivity analysis for diagnostic criteria)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (201)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.006, RR = 1.26 (1.07 to 1.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.56, I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> ‐‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CPA: cyclophosphamide; FRNS: frequently relapsing nephrotic syndrome; NA ‐ Not applicable; TwHF: <i>Tripterygium wilfordii</i> Hook F; CR: complete remission; PR: partial remission; CR+PR: complete or partial remission </p> </div> </div> <div class="table" id="CD008568-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Subgroup and sensitivity analyses comparing Tripterygium wilfordii Hook F (TwHF) with prednisone</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome or subgroup</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Studies (participants)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Statistical method</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Effect estimate (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Heterogeneity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Subgroup difference</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR (TwHF versus prednisone for non‐FRNS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (159)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.94, RR = 0.99 (0.73 to 1.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.90, I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>P = 0.17, I² = 47.7%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR (TwHF versus prednisone for FRNS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.13, RR = 1.60 (0.87 to 2.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PR (TwHF versus prednisone for non‐FRNS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (159)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.91, RR = 1.03 (0.60 to 1.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.85, I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>P = 0.82, I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PR (TwHF versus prednisone for FRNS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.71, RR = 1.07 (0.69 to 1.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR+PR (TwHF versus prednisone for non‐FRNS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (159)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.93, RR = 0.99 (0.86 to 1.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.78, I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>P = 0.06, I² = 71.7%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR+PR (TwHF versus prednisone for FRNS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.04, RR = 1.38 (1.01 to 1.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR (TwHF versus prednisone for non‐IgAN)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (187)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.42, RR = 1.13 (0.84 to 1.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.55, I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>P = 0.53, I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR (TwHF versus prednisone for IgAN)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.74, RR = 0.89 (0.44 to 1.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PR (TwHF versus prednisone for non‐IgAN)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (187)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.98, RR = 1.01 (0.63 to 1.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.94, I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>P = 0.51, I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PR (TwHF versus prednisone for IgAN)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.46, RR = 1.50 (0.51 to 4.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR+PR (TwHF versus prednisone for non‐IgAN)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (187)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.53, RR = 1.06 (0.89 to 1.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.20, I² = 35%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>P = 0.94, I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR+PR (TwHF versus prednisone for IgAN)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.70, RR = 1.08 (0.74 to 1.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR (TwHF versus prednisone for adults)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (186)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.55, RR = 1.10 (0.81 to 1.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P=0.48, I²= 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>P = 0.91, I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR (TwHF versus prednisone for elderly)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.87, RR = 1.05 (0.56 to 1.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PR (TwHF versus prednisone for adults)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (186)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.62, RR = 1.12 (0.71 to 1.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.93, I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>P = 0.53, I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PR (TwHF versus prednisone for elderly)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.62, RR = 0.71 (0.18 to 2.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR+PR (TwHF versus prednisone for adults)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (186)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.37, RR = 1.06 (0.93 to 1.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.23, I² = 31%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>P = 0.60, I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR+PR (TwHF versus prednisone for elderly)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.80, RR = 0.95 (0.62 to 1.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR (TwHF versus prednisone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (159)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.94, RR = 0.99 (0.73 to 1.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.90, I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>P = 0.17, I² = 47.7%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR (TwHF + CSA versus prednisone + CSA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.13, RR = 1.60 (0.87 to 2.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PR (TwHF versus prednisone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (159)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.91, RR = 1.03 (0.60 to 1.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.85, I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>P = 0.82, I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PR (TwHF + CSA versus prednisone + CSA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.71, RR = 1.07 (0.69 to 1.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR+PR (TwHF versus prednisone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (159)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.93, RR = 0.99 (0.86 to 1.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.78, I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>P = 0.06, I² = 71.7%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR+PR (TwHF + CSA versus prednisone + CSA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.04, RR = 1.38 (1.01 to 1.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR (sensitivity analysis for diagnostic criteria)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (137)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.40, RR = 1.17 (0.81 to 1.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.42, I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> ‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PR (sensitivity analysis for diagnostic criteria)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (137)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.65, RR = 1.14 (0.65 to 1.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.70, I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> ‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR+PR (sensitivity analysis for diagnostic criteria)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (137)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.19, RR = 1.16 (0.93 to 1.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.32, I² = 11%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> ‐‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CSA: cyclosporine; IgAN: immunoglobulin A nephropathy; FRNS: frequently relapsing nephrotic syndrome; NA ‐ Not applicable; TwHF: <i>Tripterygium wilfordii</i> Hook F; CR: complete remission; PR: partial remission; CR+PR: complete or partial remission </p> </div> </div> <section id="CD008568-sec3-0026"> <h4 class="title">TwHF versus non‐TwHF</h4> <p>Four studies compared TwHF to non‐TwHF (<a href="./references#CD008568-bbs2-0004" title="LiZ , ZhangYF , LiuF . Clinical observation of 48 cases of nephrotic syndrome treated by combined treatment of Tripterygium wilfordii and quadruple chemotherapy. Hainan Yixue [Hainan Medical Journal]1999;10(6):191‐2. LiZ , ZhangYF , LiuF . Clinical observation of 48 cases of nephrotic syndrome treated by combined treatment of Tripterygium wilfordii and quadruple chemotherapy. Yi Xue Wen Xuan [Anthology of Medicine]2000;19(2):139‐40. ">Li 2000</a>; <a href="./references#CD008568-bbs2-0005" title="SongHX , WangZT , ChenXT . Clinical study of combined treatment of cyclophosphamide and Tripterygium wilfordii for nephrotic syndrome. Lin Yi Yi Zhuan Xue Bao [Journal of Linyi Medical College]1998;20(2):109‐12. ">Song 1998</a>; <a href="./references#CD008568-bbs2-0006" title="WenYQ , ZhuQL , WangMC , RenZQ , LiuML , HuGL . Clinical therapeutic analysis of primary nephrotic syndrome treated by prednisone and Tripterygium wilfordii. Zhonghua Shenzangbing Zazhi [Chinese Journal of Nephrology]1993;9(3):190. ">Wen 1993</a>; <a href="./references#CD008568-bbs2-0008" title="ZhangF . Comparison of effects of Tripterygium glycosides plus prednisone with prednisone alone on primary nephrotic syndrome. Zhong Wai Jian Kang Wen Zhai ‐ Yi Yao Yue Kan [World Health Digest ‐ Medical Monthly]2007;4(8):96‐8. ">Zhang 2007a</a>). </p> <section id="CD008568-sec4-0016"> <h5 class="title">Primary outcomes</h5> <p>TwHF significantly increased complete remission (<a href="./references#CD008568-fig-00101" title="">Analysis 1.1</a> (4 studies, 293 participants): RR 1.46, 95% CI 1.18 to 1.80; I² = 3%) and complete or partial remission (<a href="./references#CD008568-fig-00103" title="">Analysis 1.3</a> (4 studies, 293 participants): RR 1.26, 95% CI 1.10 to 1.44; I² = 0%). The effect of TwHF on partial remission did not reach statistical significance (<a href="./references#CD008568-fig-00102" title="">Analysis 1.2</a> (4 studies, 293 participants): RR 0.77, 95% CI 0.49 to 1.21; I² = 0%). </p> </section> <section id="CD008568-sec4-0017"> <h5 class="title">Secondary outcomes</h5> <p>One study (<a href="./references#CD008568-bbs2-0008" title="ZhangF . Comparison of effects of Tripterygium glycosides plus prednisone with prednisone alone on primary nephrotic syndrome. Zhong Wai Jian Kang Wen Zhai ‐ Yi Yao Yue Kan [World Health Digest ‐ Medical Monthly]2007;4(8):96‐8. ">Zhang 2007a</a>) reported no significant difference in urinary protein excretion (<a href="./references#CD008568-fig-00104" title="">Analysis 1.4</a> (1 study, 78 participants: MD ‐0.03 g/24 h, 95% CI ‐0.21 to 0.15) and serum albumin (<a href="./references#CD008568-fig-00105" title="">Analysis 1.5</a> (1 study, 78 participants: MD 0.66 g/L, 95% CI ‐2.82 to 4.14). Two studies (<a href="./references#CD008568-bbs2-0005" title="SongHX , WangZT , ChenXT . Clinical study of combined treatment of cyclophosphamide and Tripterygium wilfordii for nephrotic syndrome. Lin Yi Yi Zhuan Xue Bao [Journal of Linyi Medical College]1998;20(2):109‐12. ">Song 1998</a>; <a href="./references#CD008568-bbs2-0008" title="ZhangF . Comparison of effects of Tripterygium glycosides plus prednisone with prednisone alone on primary nephrotic syndrome. Zhong Wai Jian Kang Wen Zhai ‐ Yi Yao Yue Kan [World Health Digest ‐ Medical Monthly]2007;4(8):96‐8. ">Zhang 2007a</a>) reported a significant decrease in serum creatinine; however heterogeneity was high (93%) and therefore we did not pool these studies (<a href="./references#CD008568-fig-00106" title="">Analysis 1.6</a>). </p> <p>One study (<a href="./references#CD008568-bbs2-0005" title="SongHX , WangZT , ChenXT . Clinical study of combined treatment of cyclophosphamide and Tripterygium wilfordii for nephrotic syndrome. Lin Yi Yi Zhuan Xue Bao [Journal of Linyi Medical College]1998;20(2):109‐12. ">Song 1998</a>) reported three types of adverse events of TwHF: infection, liver transaminase elevation, and leukopenia/bone marrow suppression. There were no significant differences in these adverse events (<a href="./references#CD008568-fig-00107" title="">Analysis 1.7</a>). </p> </section> <section id="CD008568-sec4-0018"> <h5 class="title">Subgroup analyses</h5> <p>We were unable to perform subgroup analyses for pathological diagnosis of NS and age of participants due to lack of data. </p> <section id="CD008568-sec5-0001"> <h6 class="title">SRNS or FRNS</h6> <p><a href="./references#CD008568-bbs2-0005" title="SongHX , WangZT , ChenXT . Clinical study of combined treatment of cyclophosphamide and Tripterygium wilfordii for nephrotic syndrome. Lin Yi Yi Zhuan Xue Bao [Journal of Linyi Medical College]1998;20(2):109‐12. ">Song 1998</a> included patients with SRNS or FRNS. There were no statistically significant subgroup differences in complete remission (P = 0.37), partial remission (P = 0.81) and complete or partial remission (P = 0.62) (<a href="#CD008568-tbl-0008">Table 2</a>). </p> </section> <section id="CD008568-sec5-0002"> <h6 class="title">Co‐interventions</h6> <p><a href="./references#CD008568-bbs2-0006" title="WenYQ , ZhuQL , WangMC , RenZQ , LiuML , HuGL . Clinical therapeutic analysis of primary nephrotic syndrome treated by prednisone and Tripterygium wilfordii. Zhonghua Shenzangbing Zazhi [Chinese Journal of Nephrology]1993;9(3):190. ">Wen 1993</a> and <a href="./references#CD008568-bbs2-0008" title="ZhangF . Comparison of effects of Tripterygium glycosides plus prednisone with prednisone alone on primary nephrotic syndrome. Zhong Wai Jian Kang Wen Zhai ‐ Yi Yao Yue Kan [World Health Digest ‐ Medical Monthly]2007;4(8):96‐8. ">Zhang 2007a</a> compared TwHF + prednisone versus prednisone; <a href="./references#CD008568-bbs2-0004" title="LiZ , ZhangYF , LiuF . Clinical observation of 48 cases of nephrotic syndrome treated by combined treatment of Tripterygium wilfordii and quadruple chemotherapy. Hainan Yixue [Hainan Medical Journal]1999;10(6):191‐2. LiZ , ZhangYF , LiuF . Clinical observation of 48 cases of nephrotic syndrome treated by combined treatment of Tripterygium wilfordii and quadruple chemotherapy. Yi Xue Wen Xuan [Anthology of Medicine]2000;19(2):139‐40. ">Li 2000</a> and <a href="./references#CD008568-bbs2-0005" title="SongHX , WangZT , ChenXT . Clinical study of combined treatment of cyclophosphamide and Tripterygium wilfordii for nephrotic syndrome. Lin Yi Yi Zhuan Xue Bao [Journal of Linyi Medical College]1998;20(2):109‐12. ">Song 1998</a> compared TwHF + prednisone + CPA versus prednisone + CPA. There were no statistically significant subgroup differences in complete remission (P = 0.62), partial remission (P = 0.53), and complete or partial remission (P = 0.72). </p> </section> </section> <section id="CD008568-sec4-0019"> <h5 class="title">Sensitivity analyses for diagnostic criteria</h5> <p>The diagnosis of primary NS was not confirmed until we contacted the principal investigator in one study (<a href="./references#CD008568-bbs2-0004" title="LiZ , ZhangYF , LiuF . Clinical observation of 48 cases of nephrotic syndrome treated by combined treatment of Tripterygium wilfordii and quadruple chemotherapy. Hainan Yixue [Hainan Medical Journal]1999;10(6):191‐2. LiZ , ZhangYF , LiuF . Clinical observation of 48 cases of nephrotic syndrome treated by combined treatment of Tripterygium wilfordii and quadruple chemotherapy. Yi Xue Wen Xuan [Anthology of Medicine]2000;19(2):139‐40. ">Li 2000)</a>. This study was excluded from the sensitivity analysis. There were no significant changes of complete, partial, and complete or partial remission (additional <a href="#CD008568-tbl-0008">Table 2</a>). </p> </section> </section> <section id="CD008568-sec3-0027"> <h4 class="title">TwHF versus prednisone</h4> <p>Four studies compared TwHF to prednisone (<a href="./references#CD008568-bbs2-0001" title="A‐DaLT , SuJH , WangZC . Clinical random control observation of 18 cases of patients with primary IgA nephropathy syndrome treated with tripterygium glycosides tablet. Dangdai Yixue [China Contemporary Medicine]2008;15(10):12‐3. ">A‐Da 2008</a>; <a href="./references#CD008568-bbs2-0003" title="HanJH , MouZL , WangJP . Combination of Tripterygium glycosides and cyclosporin A for the treatment of refractory nephrotic syndrome. Linchuang Huicui [Clinical Focus]1999;14(18):841‐2. ">Han 1999</a>; <a href="./references#CD008568-bbs2-0007" title="YuanDS , WangYR . Clinical therapeutic analysis of primary nephrotic syndrome in elderly treated by combination treatment of Tripterygium wilfordii and medium dosage prednisone. Zhong Hua Lin Chuang Yi Xue Yan Jiu Za Zhi [Chinese Magazine of Clinical Medicinal Professional Research]2003;9(12):11475‐6. ">Yuan 2003</a>; <a href="./references#CD008568-bbs2-0009" title="ZhaoDG , ZhaoX . Synergism of Tripterygium glycosides and prednisone for the complementary treatment of nephrotic syndrome. Changchun Zhongyiyao Daxue Xuebao [Journal of Changchun University of Traditional Chinese Medicine]1997;13(4):20‐1. ">Zhao 1997</a>). </p> <section id="CD008568-sec4-0020"> <h5 class="title">Primary outcomes</h5> <p>There were no significant differences in complete remission (<a href="./references#CD008568-fig-00201" title="">Analysis 2.1</a> (4 studies, 223 participants): RR 1.09, 95% CI 0.83 to 1.43, I² = 0%), partial remission (<a href="./references#CD008568-fig-00202" title="">Analysis 2.2</a> (4 studies, 223 participants): RR 1.07, 95% CI 0.69 to 1.65, I² = 0%), or complete or partial remission (<a href="./references#CD008568-fig-00203" title="">Analysis 2.3</a> (4 studies, 223 participants): RR 1.06, 95% CI 0.92 to 1.22, I² = 14%). </p> </section> <section id="CD008568-sec4-0021"> <h5 class="title">Secondary outcomes</h5> <p>Urinary protein excretion, serum albumin, and serum creatinine were not reported.</p> <p>Two studies (<a href="./references#CD008568-bbs2-0003" title="HanJH , MouZL , WangJP . Combination of Tripterygium glycosides and cyclosporin A for the treatment of refractory nephrotic syndrome. Linchuang Huicui [Clinical Focus]1999;14(18):841‐2. ">Han 1999</a>; <a href="./references#CD008568-bbs2-0007" title="YuanDS , WangYR . Clinical therapeutic analysis of primary nephrotic syndrome in elderly treated by combination treatment of Tripterygium wilfordii and medium dosage prednisone. Zhong Hua Lin Chuang Yi Xue Yan Jiu Za Zhi [Chinese Magazine of Clinical Medicinal Professional Research]2003;9(12):11475‐6. ">Yuan 2003</a>) showed no significant difference in liver transaminase elevation (<a href="./references#CD008568-fig-00204" title="">Analysis 2.4</a>.1 (2 studies 101 participants): RR 1.51, 95% CI 0.16 to 14.22; I² = 47%). <a href="./references#CD008568-bbs2-0007" title="YuanDS , WangYR . Clinical therapeutic analysis of primary nephrotic syndrome in elderly treated by combination treatment of Tripterygium wilfordii and medium dosage prednisone. Zhong Hua Lin Chuang Yi Xue Yan Jiu Za Zhi [Chinese Magazine of Clinical Medicinal Professional Research]2003;9(12):11475‐6. ">Yuan 2003</a> reported no significant difference for leukopenia or bone marrow suppression, elevated blood pressure, elevated blood glucose, femoral head necrosis, and infection. One study (<a href="./references#CD008568-bbs2-0007" title="YuanDS , WangYR . Clinical therapeutic analysis of primary nephrotic syndrome in elderly treated by combination treatment of Tripterygium wilfordii and medium dosage prednisone. Zhong Hua Lin Chuang Yi Xue Yan Jiu Za Zhi [Chinese Magazine of Clinical Medicinal Professional Research]2003;9(12):11475‐6. ">Yuan 2003</a>) reported the risk of psychosis was significantly lower in the TwHF group compared to the prednisone group (<a href="./references#CD008568-fig-00204" title="">Analysis 2.4</a>.7 (1 study, 37 participants): RR 0.11, 95% CI 0.01 to 0.75). </p> </section> <section id="CD008568-sec4-0022"> <h5 class="title">Subgroup analyses</h5> <section id="CD008568-sec5-0003"> <h6 class="title">SRNS or FRNS</h6> <p><a href="./references#CD008568-bbs2-0003" title="HanJH , MouZL , WangJP . Combination of Tripterygium glycosides and cyclosporin A for the treatment of refractory nephrotic syndrome. Linchuang Huicui [Clinical Focus]1999;14(18):841‐2. ">Han 1999</a> only enrolled patients with SRNS or FRNS. There were no statistically significant subgroup differences in complete remission (P = 0.17), partial remission (P = 0.82) and complete or partial remission (P = 0.06) (additional <a href="#CD008568-tbl-0009">Table 3</a>). </p> </section> <section id="CD008568-sec5-0004"> <h6 class="title">Pathological diagnosis of NS</h6> <p><a href="./references#CD008568-bbs2-0001" title="A‐DaLT , SuJH , WangZC . Clinical random control observation of 18 cases of patients with primary IgA nephropathy syndrome treated with tripterygium glycosides tablet. Dangdai Yixue [China Contemporary Medicine]2008;15(10):12‐3. ">A‐Da 2008</a> included only patients with IgA nephropathy‐induced primary NS. There were no significant subgroup differences in complete remission (P = 0.53), partial remission (P = 0.51), and complete or partial remission (P = 0.94). </p> </section> <section id="CD008568-sec5-0005"> <h6 class="title">Aged participants</h6> <p><a href="./references#CD008568-bbs2-0007" title="YuanDS , WangYR . Clinical therapeutic analysis of primary nephrotic syndrome in elderly treated by combination treatment of Tripterygium wilfordii and medium dosage prednisone. Zhong Hua Lin Chuang Yi Xue Yan Jiu Za Zhi [Chinese Magazine of Clinical Medicinal Professional Research]2003;9(12):11475‐6. ">Yuan 2003</a> only enrolled elderly patients. There were no significant subgroup differences in complete remission (P = 0.91), partial remission (P = 0.53), and complete or partial remission (P = 0.60) </p> </section> <section id="CD008568-sec5-0006"> <h6 class="title">Co‐interventions</h6> <p><a href="./references#CD008568-bbs2-0001" title="A‐DaLT , SuJH , WangZC . Clinical random control observation of 18 cases of patients with primary IgA nephropathy syndrome treated with tripterygium glycosides tablet. Dangdai Yixue [China Contemporary Medicine]2008;15(10):12‐3. ">A‐Da 2008</a>, <a href="./references#CD008568-bbs2-0007" title="YuanDS , WangYR . Clinical therapeutic analysis of primary nephrotic syndrome in elderly treated by combination treatment of Tripterygium wilfordii and medium dosage prednisone. Zhong Hua Lin Chuang Yi Xue Yan Jiu Za Zhi [Chinese Magazine of Clinical Medicinal Professional Research]2003;9(12):11475‐6. ">Yuan 2003</a> and <a href="./references#CD008568-bbs2-0009" title="ZhaoDG , ZhaoX . Synergism of Tripterygium glycosides and prednisone for the complementary treatment of nephrotic syndrome. Changchun Zhongyiyao Daxue Xuebao [Journal of Changchun University of Traditional Chinese Medicine]1997;13(4):20‐1. ">Zhao 1997</a> compared TwHF and prednisone; and <a href="./references#CD008568-bbs2-0003" title="HanJH , MouZL , WangJP . Combination of Tripterygium glycosides and cyclosporin A for the treatment of refractory nephrotic syndrome. Linchuang Huicui [Clinical Focus]1999;14(18):841‐2. ">Han 1999</a> compared TwHF + cyclosporine versus prednisone + cyclosporine. There were no statistically significant subgroup differences in complete remission (P = 0.17), partial remission (P = 0.82) and complete or partial remission (P = 0.06). </p> </section> </section> <section id="CD008568-sec4-0023"> <h5 class="title">Sensitivity analyses for diagnostic criteria</h5> <p>The diagnosis of primary NS was not confirmed until we contacted the principal investigator in one study (<a href="./references#CD008568-bbs2-0009" title="ZhaoDG , ZhaoX . Synergism of Tripterygium glycosides and prednisone for the complementary treatment of nephrotic syndrome. Changchun Zhongyiyao Daxue Xuebao [Journal of Changchun University of Traditional Chinese Medicine]1997;13(4):20‐1. ">Zhao 1997</a>). This study was excluded from the sensitivity analysis. There were no significant changes of complete, partial, and complete or partial remission (additional <a href="#CD008568-tbl-0009">Table 3</a>). </p> </section> </section> <section id="CD008568-sec3-0028"> <h4 class="title">TwHF versus CPA</h4> <p>Two studies compared TwHF with CPA (<a href="./references#CD008568-bbs2-0002" title="ChenZM , ChenZJ . Clinical analysis of 36 cases of refractory nephrotic syndrome treated by high‐dosage Tripterygium glycosides. Zhongguo Quanke Yixue [Chinese General Practice]2003;6(11):948. ">Chen 2003</a>; <a href="./references#CD008568-bbs2-0010" title="ZhaoL . Comparative observation of effects of Tripterygium glycosides versus cyclophosphamide for the treatment of refractory nephrotic syndrome. Hebei Yi Yao [Hebei Medical Journal]2009;31(16):2160‐1. ">Zhao 2009</a>). </p> <section id="CD008568-sec4-0024"> <h5 class="title">Primary outcomes</h5> <p>There were no significant differences in complete remission (<a href="./references#CD008568-fig-00301" title="">Analysis 3.1</a> (2 studies, 114 participants): RR 1.06, 95% CI 0.82 to 1.37; I² = 0%), partial remission (<a href="./references#CD008568-fig-00302" title="">Analysis 3.2</a> (2 studies, 114 participants): RR 1.02, 95% CI 0.46 to 2.29; I² = 0%), and complete or partial remission (<a href="./references#CD008568-fig-00303" title="">Analysis 3.3</a> (2 studies, 114 participants); RR 1.05, 95% CI 0.90 to 1.23; I² = 0%). </p> </section> <section id="CD008568-sec4-0025"> <h5 class="title">Secondary outcomes</h5> <p>One study reported no significant differences in urinary protein excretion (<a href="./references#CD008568-fig-00304" title="">Analysis 3.4</a> (1 study, 46 participants): MD ‐0.30 g/24 h, 95% CI ‐1.34 to 0.74) and serum albumin (<a href="./references#CD008568-fig-00305" title="">Analysis 3.5</a> (1 study, 46 participants): MD 1.00 g/L, 95% CI ‐1.91 to 3.91). This study reported TwHF was associated with a significant decrease in serum creatinine (<a href="./references#CD008568-fig-00306" title="">Analysis 3.6</a> (1 study, 46 participants): MD ‐14.00 μmol/L, 95% CI ‐26.43 to ‐1.57). </p> <p>There were no significant differences in the following adverse events: gastrointestinal discomfort, liver transaminase elevation, menstrual disorders, leukopenia and haemorrhagic cystitis. The risk of hair loss was significantly lower for the TwHF group compared to the CPA group (<a href="./references#CD008568-fig-00307" title="">Analysis 3.7</a>.5 (2 studies, 114 participants): RR 0.11, 95% CI 0.02 to 0.59; I² = 0%). Subgroup and sensitivity analyses were not performed due to the lack of data. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008568-sec1-0006" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008568-sec1-0006"></div> <section id="CD008568-sec2-0011"> <h3 class="title" id="CD008568-sec2-0011">Summary of main results</h3> <p>This systematic review provides some support for the effectiveness of TwHF for the treatment of primary NS; however the quality of evidence was suboptimal because of the small number of included studies enrolling small numbers of participants; short follow‐up in each study; only a few studies in each comparison category; and major concerns with methodological bias. TwHF could significantly increase complete remission by 46% (18% to 80%) and complete or partial remission by 26% (10% to 44%). In a population with an expected rate of complete remission of 436/1000, TwHF could increase the number of patients achieving complete remission to 637/1000 (514 to 785). Complete or partial remission could be increased from 664 to 837/1000 (730 to 956). Meta‐analyses of head‐to‐head comparisons demonstrated that there were no significant differences in the primary outcomes when TwHF was compared with either prednisone or CPA. Few studies reported data on secondary outcomes ‐ proteinuria, serum albumin and serum creatinine; one study reported TwHF could significantly decrease serum creatinine compared with CPA. Issues of safety varied considerably and still remain unclear due to the poor reporting of adverse events and the variety of toxicity profiles. Compared to prednisone, TwHF was associated with a lower risk of psychosis. Patients treated with TwHF had a lower risk of hair loss when compared with CPA. However there were no significant differences in other adverse events, including reversible amenorrhoea, leukopenia, liver transaminase elevation, and gastrointestinal discomfort. A double‐blind, placebo‐controlled study examined the safety and efficacy of TwHF in the treatment of rheumatoid arthritis (<a href="./references#CD008568-bbs2-0076" title="TaoX , YoungerJ , FanFZ , WangB , LipskyPE . Benefit of an extract of Tripterygium Wilfordii Hook F in patients with rheumatoid arthritis: a double‐blind, placebo‐controlled study. Arthritis &amp; Rheumatism2002;46(7):1735‐43. [MEDLINE: 12124856] ">Tao 2002</a>). Although the dose in <a href="./references#CD008568-bbs2-0076" title="TaoX , YoungerJ , FanFZ , WangB , LipskyPE . Benefit of an extract of Tripterygium Wilfordii Hook F in patients with rheumatoid arthritis: a double‐blind, placebo‐controlled study. Arthritis &amp; Rheumatism2002;46(7):1735‐43. [MEDLINE: 12124856] ">Tao 2002</a> was 180 mg/d to 360 mg/d for 20 weeks ‐ higher than in any of the 10 included studies (0.5 to 2.0 mg/kg/d for 4 to 8 weeks as initial therapy) ‐ no serious adverse events were observed, and no patients withdrew because of adverse events. </p> </section> <section id="CD008568-sec2-0012"> <h3 class="title" id="CD008568-sec2-0012">Overall completeness and applicability of evidence</h3> <p>All included studies were conducted in Chinese patients and published in Chinese language journals. Evidence is still needed to examine the effects of TwHF for other ethnicities. There was little evidence related to the use of TwHF in children with NS. In Chinese clinical practice many physicians were reluctant to use TwHF for children to avoid reproductive system complications (<a href="./references#CD008568-bbs2-0004" title="LiZ , ZhangYF , LiuF . Clinical observation of 48 cases of nephrotic syndrome treated by combined treatment of Tripterygium wilfordii and quadruple chemotherapy. Hainan Yixue [Hainan Medical Journal]1999;10(6):191‐2. LiZ , ZhangYF , LiuF . Clinical observation of 48 cases of nephrotic syndrome treated by combined treatment of Tripterygium wilfordii and quadruple chemotherapy. Yi Xue Wen Xuan [Anthology of Medicine]2000;19(2):139‐40. ">Li 2000</a>). Pathological variations may differ in response to TwHF treatment; however due to the paucity of evidence we unable to use subgroup analyses to determine whether those variations could convey different responses to TwHF treatment. Although four studies enrolled patients with SRNS or FRNS, heterogeneity in the interventions among these four studies did not allow us to examine the effect of TwHF on patients with SRNS or FRNS. </p> </section> <section id="CD008568-sec2-0013"> <h3 class="title" id="CD008568-sec2-0013">Quality of the evidence</h3> <p>This review included 10 studies (630 participants). Assessment according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group indicated that the results could be considered as low quality level. The suboptimal methodological quality of the included studies was the major contributing factor. No study demonstrated adequate allocation concealment. Effect estimates from studies with inadequate concealment of allocation have been shown to overestimate beneficial effects by 18% (95% CI 5% to 29%) than that from studies with adequate concealment of allocation (<a href="./references#CD008568-bbs2-0068" title="PildalJ , HrobjartssonA , JorgensenKJ , HildenJ , AltmanDG , GotzschePC . Impact of allocation concealment on conclusions drawn from meta‐analyses of randomized trials. International Journal of Epidemiology2007;36(4):847‐57. [MEDLINE: 17517809] ">Pildal 2007</a>). Blinding was not reported in any study. The outcome measurements were all objective and were not likely to be influenced by lack of blinding; however lack of blinding could introduce potential bias in clinical studies (<a href="./references#CD008568-bbs2-0059" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). Although primary outcome completeness rates were 100%, this was remarkably lower for secondary outcomes (20% to 50%). Consequently, selective outcome reporting bias should be considered when interpreting the results. </p> <p>Both the numbers of included studies and participants were relatively small, and all tested comparisons involved no more than four studies. Follow‐up duration was no more than 18 months. The paucity of evidence did not allow us to perform subgroup analyses to explore modification effects by age, pathological variations, clinical conditions, and co‐interventions. Such modification effects may potentially influence the efficacy of TwHF and should be investigated in the future. None of the included studies were designed to evaluate the efficacy of within intervention differences, such as dose and duration variation. More and better evidence is needed to explore benefits that may be conferred by different doses and durations of TwHF treatment. </p> </section> <section id="CD008568-sec2-0014"> <h3 class="title" id="CD008568-sec2-0014">Potential biases in the review process</h3> <p>Assessment of publication bias was not conducted because of the small number of included studies in the three comparisons. All studies were reported in Chinese language journals. Therefore, publication bias and language bias should be carefully considered when interpreting these results. </p> </section> <section id="CD008568-sec2-0015"> <h3 class="title" id="CD008568-sec2-0015">Agreements and disagreements with other studies or reviews</h3> <p><a href="./references#CD008568-bbs2-0080" title="XuG , TuW , JiangD , XuC . Tripterygium wilfordii Hook F treatment for idiopathic refractory nephrotic syndrome in adults: a meta‐analysis. Nephron. Clinical Practice2009;111(4):c223‐8. [MEDLINE: 19287181] ">Xu 2009a</a> meta‐analysed results from three studies enrolling 150 adult patients with primary refractory NS. TwHF significantly increased complete remission (OR 2.81, 95% CI 1.26 to 6.30) and complete or partial remission (OR 3.25, 95% CI 1.20 to 8.76). The efficacy of TwHF on primary IgA nephropathy was examined in another meta‐analysis of four studies with 188 patients (<a href="./references#CD008568-bbs2-0054" title="ChenYZ , GaoQ , ZhaoXZ , ChenXM , ZhangF , ChenJ , et al. Meta‐analysis of Tripterygium wilfordii hook F in the immunosuppressive treatment of IgA nephropathy. Internal Medicine2010;49(19):2049‐55. [MEDLINE: 20930429] ">Chen 2010a</a>). TwHF significantly increased complete remission (RR 1.53, 95% CI 1.09 to 2.16) and complete or partial remission (RR 1.27, 95% CI 1.08 to 1.48). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008568-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/urn:x-wiley:14651858:media:CD008568:CD008568-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_t/tCD008568-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Flow diagram of study selection" data-id="CD008568-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_n/nCD008568-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow diagram of study selection</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/full#CD008568-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_n/nCD008568-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008568-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/urn:x-wiley:14651858:media:CD008568:CD008568-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_t/tCD008568-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD008568-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_n/nCD008568-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/full#CD008568-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_n/nCD008568-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008568-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/urn:x-wiley:14651858:media:CD008568:CD008568-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_t/tCD008568-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD008568-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_n/nCD008568-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/full#CD008568-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_n/nCD008568-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008568-fig-00101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/urn:x-wiley:14651858:media:CD008568:CD008568-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_t/tCD008568-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TwHF versus no TwHF, Outcome 1 Complete remission." data-id="CD008568-fig-00101" src="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_n/nCD008568-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 TwHF versus no TwHF, Outcome 1 Complete remission.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/references#CD008568-fig-00101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_n/nCD008568-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008568-fig-00102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/urn:x-wiley:14651858:media:CD008568:CD008568-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_t/tCD008568-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TwHF versus no TwHF, Outcome 2 Partial remission." data-id="CD008568-fig-00102" src="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_n/nCD008568-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 TwHF versus no TwHF, Outcome 2 Partial remission.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/references#CD008568-fig-00102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_n/nCD008568-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008568-fig-00103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/urn:x-wiley:14651858:media:CD008568:CD008568-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_t/tCD008568-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TwHF versus no TwHF, Outcome 3 Complete or partial remission." data-id="CD008568-fig-00103" src="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_n/nCD008568-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 TwHF versus no TwHF, Outcome 3 Complete or partial remission.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/references#CD008568-fig-00103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_n/nCD008568-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008568-fig-00104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/urn:x-wiley:14651858:media:CD008568:CD008568-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_t/tCD008568-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TwHF versus no TwHF, Outcome 4 Urinary protein excretion." data-id="CD008568-fig-00104" src="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_n/nCD008568-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 TwHF versus no TwHF, Outcome 4 Urinary protein excretion.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/references#CD008568-fig-00104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_n/nCD008568-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008568-fig-00105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/urn:x-wiley:14651858:media:CD008568:CD008568-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_t/tCD008568-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TwHF versus no TwHF, Outcome 5 Serum albumin." data-id="CD008568-fig-00105" src="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_n/nCD008568-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 TwHF versus no TwHF, Outcome 5 Serum albumin.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/references#CD008568-fig-00105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_n/nCD008568-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008568-fig-00106"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/urn:x-wiley:14651858:media:CD008568:CD008568-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_t/tCD008568-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TwHF versus no TwHF, Outcome 6 Serum creatinine." data-id="CD008568-fig-00106" src="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_n/nCD008568-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 TwHF versus no TwHF, Outcome 6 Serum creatinine.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/references#CD008568-fig-00106">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_n/nCD008568-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008568-fig-00107"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/urn:x-wiley:14651858:media:CD008568:CD008568-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_t/tCD008568-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TwHF versus no TwHF, Outcome 7 Adverse effects." data-id="CD008568-fig-00107" src="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_n/nCD008568-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 TwHF versus no TwHF, Outcome 7 Adverse effects.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/references#CD008568-fig-00107">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_n/nCD008568-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008568-fig-00201"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/urn:x-wiley:14651858:media:CD008568:CD008568-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_t/tCD008568-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 TwHF versus prednisone, Outcome 1 Complete remission." data-id="CD008568-fig-00201" src="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_n/nCD008568-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 TwHF versus prednisone, Outcome 1 Complete remission.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/references#CD008568-fig-00201">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_n/nCD008568-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008568-fig-00202"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/urn:x-wiley:14651858:media:CD008568:CD008568-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_t/tCD008568-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 TwHF versus prednisone, Outcome 2 Partial remission." data-id="CD008568-fig-00202" src="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_n/nCD008568-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 TwHF versus prednisone, Outcome 2 Partial remission.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/references#CD008568-fig-00202">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_n/nCD008568-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008568-fig-00203"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/urn:x-wiley:14651858:media:CD008568:CD008568-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_t/tCD008568-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 TwHF versus prednisone, Outcome 3 Complete or partial remission." data-id="CD008568-fig-00203" src="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_n/nCD008568-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 TwHF versus prednisone, Outcome 3 Complete or partial remission.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/references#CD008568-fig-00203">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_n/nCD008568-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008568-fig-00204"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/urn:x-wiley:14651858:media:CD008568:CD008568-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_t/tCD008568-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 TwHF versus prednisone, Outcome 4 Adverse effects." data-id="CD008568-fig-00204" src="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_n/nCD008568-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 TwHF versus prednisone, Outcome 4 Adverse effects.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/references#CD008568-fig-00204">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_n/nCD008568-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008568-fig-00301"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/urn:x-wiley:14651858:media:CD008568:CD008568-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_t/tCD008568-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 TwHF versus CPA, Outcome 1 Complete remission." data-id="CD008568-fig-00301" src="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_n/nCD008568-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 TwHF versus CPA, Outcome 1 Complete remission.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/references#CD008568-fig-00301">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_n/nCD008568-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008568-fig-00302"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/urn:x-wiley:14651858:media:CD008568:CD008568-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_t/tCD008568-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 TwHF versus CPA, Outcome 2 Partial remission." data-id="CD008568-fig-00302" src="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_n/nCD008568-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 TwHF versus CPA, Outcome 2 Partial remission.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/references#CD008568-fig-00302">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_n/nCD008568-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008568-fig-00303"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/urn:x-wiley:14651858:media:CD008568:CD008568-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_t/tCD008568-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 TwHF versus CPA, Outcome 3 Complete or partial remission." data-id="CD008568-fig-00303" src="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_n/nCD008568-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 TwHF versus CPA, Outcome 3 Complete or partial remission.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/references#CD008568-fig-00303">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_n/nCD008568-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008568-fig-00304"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/urn:x-wiley:14651858:media:CD008568:CD008568-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_t/tCD008568-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 TwHF versus CPA, Outcome 4 Urinary protein excretion." data-id="CD008568-fig-00304" src="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_n/nCD008568-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 TwHF versus CPA, Outcome 4 Urinary protein excretion.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/references#CD008568-fig-00304">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_n/nCD008568-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008568-fig-00305"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/urn:x-wiley:14651858:media:CD008568:CD008568-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_t/tCD008568-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 TwHF versus CPA, Outcome 5 Serum albumin." data-id="CD008568-fig-00305" src="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_n/nCD008568-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 TwHF versus CPA, Outcome 5 Serum albumin.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/references#CD008568-fig-00305">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_n/nCD008568-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008568-fig-00306"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/urn:x-wiley:14651858:media:CD008568:CD008568-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_t/tCD008568-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 TwHF versus CPA, Outcome 6 Serum creatinine." data-id="CD008568-fig-00306" src="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_n/nCD008568-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 TwHF versus CPA, Outcome 6 Serum creatinine.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/references#CD008568-fig-00306">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_n/nCD008568-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008568-fig-00307"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/urn:x-wiley:14651858:media:CD008568:CD008568-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_t/tCD008568-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 TwHF versus CPA, Outcome 7 Adverse effects." data-id="CD008568-fig-00307" src="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_n/nCD008568-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 TwHF versus CPA, Outcome 7 Adverse effects.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/references#CD008568-fig-00307">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/media/CDSR/CD008568/image_n/nCD008568-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008568-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings: Tripterygium wilfordii Hook F (TwHF) versus no TwHF</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="6" rowspan="1" valign=""> <p><b> TwHF versus non‐TwHF for primary nephrotic syndrome</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="6" rowspan="1" valign=""> <p><b> Patient or population: patients with primary nephrotic syndrome<br/> Settings: <br/> Intervention: <i>Tripterygium wilfordii</i> Hook F (TwHF)<br/> Comparison: no TwHF</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Non‐TwHF</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> TwHF</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Complete remission</b> (follow‐up: 12 to 16 months) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.46</b> <br/> (1.18 to 1.80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>293 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>436 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>637 per 1000</b> <br/> (514 to 785) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>406 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>593 per 1000</b> <br/> (479 to 731) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Partial remission</b> (follow‐up: 12 to 16 months) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.77</b> <br/> (0.49 to 1.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>293 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>229 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>176 per 1000</b> <br/> (112 to 277) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>257 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>198 per 1000</b> <br/> (126 to 311) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Complete or partial remission</b> (follow‐up: 12 to 16 months) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.26</b> <br/> (1.1 to 1.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>293 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>664 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>837 per 1000</b> <br/> (730 to 956) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>662 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>834 per 1000</b> <br/> (728 to 953) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/> <b>Very low quality:</b> we are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Small number of studies and patients, short follow‐up, and major concerns with methodological bias.<br/> <sup>2</sup> Language bias should be considered because all included studies were conducted in Chinese patients and published in Chinese language. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings: Tripterygium wilfordii Hook F (TwHF) versus no TwHF</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/full#CD008568-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008568-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings: Tripterygium wilfordii Hook F versus prednisone</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="6" rowspan="1" valign=""> <p><b><i>Tripterygium wilfordii</i> Hook F (TwHF) versus prednisone for primary nephrotic syndrome</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="6" rowspan="1" valign=""> <p><b> Patient or population: patients with primary nephrotic syndrome<br/> Settings: <br/> Intervention: TwHF<br/> Comparison: prednisone</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Prednisone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> TwHF</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Complete remission</b> (follow‐up: 6 to 18 months) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.09</b> <br/> (0.83 to 1.43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>223 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>462 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>504 per 1000</b> <br/> (383 to 661) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>545 per 1000</b> <br/> (415 to 715) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Partial remission</b> (follow‐up: 6 to 18 months) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.07</b> <br/> (0.69 to 1.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>223 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>269 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>288 per 1000</b> <br/> (186 to 444) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>290 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>310 per 1000</b> <br/> (200 to 478) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Complete or partial remission</b> (follow‐up: 6 to 18 months) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.05</b> <br/> (0.92 to 1.2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>223 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>731 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>768 per 1000</b> <br/> (673 to 877) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>722 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>758 per 1000</b> <br/> (664 to 866) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/> <b>Very low quality:</b> we are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Small number of studies and patients, short follow‐up, and major concerns with methodological bias.<br/> <sup>2</sup> Language bias should be considered because all included studies were conducted in Chinese patients and published in Chinese language. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings: Tripterygium wilfordii Hook F versus prednisone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/full#CD008568-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008568-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings: Comparison of TwHF and CPA</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="6" rowspan="1" valign=""> <p><b><i>Tripterygium wilfordii</i> Hook F (TwHF)versus cyclophosphamide (CPA)for primary nephrotic syndrome</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="6" rowspan="1" valign=""> <p><b> Patient or population: patients with primary nephrotic syndrome<br/> Settings: <br/> Intervention: TwHF<br/> Comparison: CPA</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>CPA</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> TwHF</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Complete remission</b> (follow‐up: 3 to 12 months) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.06</b> <br/> (0.82 to 1.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>114 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>654 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>693 per 1000</b> <br/> (536 to 896) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>653 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>692 per 1000</b> <br/> (535 to 895) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Partial remission</b> (follow‐up: 3 to 12 months) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.02</b> <br/> (0.46 to 2.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>114 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>173 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>176 per 1000</b> <br/> (80 to 396) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>169 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>172 per 1000</b> <br/> (78 to 387) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Complete or partial remission</b> (follow‐up: 3 to 12 months) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.05</b> <br/> (0.9 to 1.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>114 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>827 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>868 per 1000</b> <br/> (744 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>822 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>863 per 1000</b> <br/> (740 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) was based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/> <b>Very low quality:</b> we are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Small number of studies and patients, short follow‐up, and major concerns with methodological bias.<br/> <sup>2</sup> Language bias should be considered because all included studies were conducted in Chinese patients and published in Chinese language </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings: Comparison of TwHF and CPA</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/full#CD008568-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008568-tbl-0007"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Study treatment, control and comparison groups</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>follow‐up (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Co‐interventions</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b> TwHF versus non‐TwHF</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008568-bbs2-0004" title="LiZ , ZhangYF , LiuF . Clinical observation of 48 cases of nephrotic syndrome treated by combined treatment of Tripterygium wilfordii and quadruple chemotherapy. Hainan Yixue [Hainan Medical Journal]1999;10(6):191‐2. LiZ , ZhangYF , LiuF . Clinical observation of 48 cases of nephrotic syndrome treated by combined treatment of Tripterygium wilfordii and quadruple chemotherapy. Yi Xue Wen Xuan [Anthology of Medicine]2000;19(2):139‐40. ">Li 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TwHF + prednisone + CPA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prednisone + CPA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same co‐interventions and doses in each arm</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008568-bbs2-0005" title="SongHX , WangZT , ChenXT . Clinical study of combined treatment of cyclophosphamide and Tripterygium wilfordii for nephrotic syndrome. Lin Yi Yi Zhuan Xue Bao [Journal of Linyi Medical College]1998;20(2):109‐12. ">Song 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TwHF + prednisone + CPA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prednisone + CPA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12‐15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same co‐interventions and doses in each arm</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008568-bbs2-0006" title="WenYQ , ZhuQL , WangMC , RenZQ , LiuML , HuGL . Clinical therapeutic analysis of primary nephrotic syndrome treated by prednisone and Tripterygium wilfordii. Zhonghua Shenzangbing Zazhi [Chinese Journal of Nephrology]1993;9(3):190. ">Wen 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TwHF + prednisone (1.0 mg/kg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prednisone (1.0 mg/kg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12‐16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same co‐interventions and doses in each arm</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008568-bbs2-0008" title="ZhangF . Comparison of effects of Tripterygium glycosides plus prednisone with prednisone alone on primary nephrotic syndrome. Zhong Wai Jian Kang Wen Zhai ‐ Yi Yao Yue Kan [World Health Digest ‐ Medical Monthly]2007;4(8):96‐8. ">Zhang 2007a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TwHF + prednisone (1.0 mg/kg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prednisone (1.0 mg/kg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same co‐interventions and doses in each arm</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b> TwHF versus prednisone</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008568-bbs2-0001" title="A‐DaLT , SuJH , WangZC . Clinical random control observation of 18 cases of patients with primary IgA nephropathy syndrome treated with tripterygium glycosides tablet. Dangdai Yixue [China Contemporary Medicine]2008;15(10):12‐3. ">A‐Da 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TwHF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prednisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same co‐interventions and doses in each arm</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008568-bbs2-0003" title="HanJH , MouZL , WangJP . Combination of Tripterygium glycosides and cyclosporin A for the treatment of refractory nephrotic syndrome. Linchuang Huicui [Clinical Focus]1999;14(18):841‐2. ">Han 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TwHF + CSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prednisone + CSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same co‐interventions and doses in each arm</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008568-bbs2-0007" title="YuanDS , WangYR . Clinical therapeutic analysis of primary nephrotic syndrome in elderly treated by combination treatment of Tripterygium wilfordii and medium dosage prednisone. Zhong Hua Lin Chuang Yi Xue Yan Jiu Za Zhi [Chinese Magazine of Clinical Medicinal Professional Research]2003;9(12):11475‐6. ">Yuan 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TwHF + prednisone (0.4 to 0.5 mg/kg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prednisone (0.8 to 1.0 mg/kg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12‐18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same co‐interventions and doses in each arm</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008568-bbs2-0009" title="ZhaoDG , ZhaoX . Synergism of Tripterygium glycosides and prednisone for the complementary treatment of nephrotic syndrome. Changchun Zhongyiyao Daxue Xuebao [Journal of Changchun University of Traditional Chinese Medicine]1997;13(4):20‐1. ">Zhao 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TwHF + prednisone (0.6 mg/kg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prednisone (1.0 mg/kg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10‐12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same co‐interventions and doses in each arm</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008568-bbs2-0009" title="ZhaoDG , ZhaoX . Synergism of Tripterygium glycosides and prednisone for the complementary treatment of nephrotic syndrome. Changchun Zhongyiyao Daxue Xuebao [Journal of Changchun University of Traditional Chinese Medicine]1997;13(4):20‐1. ">Zhao 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TwHF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prednisone (1.0 mg/kg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10‐12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same co‐interventions and doses in each arm</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b> TwHF versus CPA</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008568-bbs2-0002" title="ChenZM , ChenZJ . Clinical analysis of 36 cases of refractory nephrotic syndrome treated by high‐dosage Tripterygium glycosides. Zhongguo Quanke Yixue [Chinese General Practice]2003;6(11):948. ">Chen 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TwHF + prednisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CPA + prednisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same co‐interventions and doses in each arm</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008568-bbs2-0010" title="ZhaoL . Comparative observation of effects of Tripterygium glycosides versus cyclophosphamide for the treatment of refractory nephrotic syndrome. Hebei Yi Yao [Hebei Medical Journal]2009;31(16):2160‐1. ">Zhao 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TwHF + prednisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CPA + prednisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same co‐interventions and doses in each arm</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>CPA: cyclophosphamide; CSA: cyclosporine; TwHF: <i>Tripterygium wilfordii</i> Hook F </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Study treatment, control and comparison groups</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/full#CD008568-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008568-tbl-0008"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Subgroup and sensitivity analyses comparing Tripterygium wilfordii Hook F (TwHF) with no TwHF</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome or subgroup</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Studies (participants)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Statistical method</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Effect estimate (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Heterogeneity</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Subgroup difference</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR (TwHF versus no TwHF for non‐FRNS)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (235)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.004, RR = 1.41 (1.11 to 1.79)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.33, I² = 10%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>P = 0.37, I² = 0%</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR (TwHF versus no TwHF for FRNS)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1(58)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.03, RR = 1.87 (1.07 to 3.26)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PR (TwHF versus no TWHF for non‐FRNS)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (235)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.39, RR = 0.80 (0.48 to 1.33)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.79, I² = 0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>P = 0.81, I² = 0%</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PR (TwHF versus no TwHF for FRNS)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (58)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.45, RR = 0.70 (0.28 to 1.76)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR+PR (TwHF versus no TwHF for non‐FRNS)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (235)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.005, RR = 1.24 (1.07 to 1.43)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.64, I² = 0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>P = 0.62, I² = 0%</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR+PR (TwHF versus no TwHF for FRNS)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (58)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.06, RR = 1.35 (0.99 to 1.84)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR (TwHF + prednisone versus prednisone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (143)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.14, RR = 1.43 (0.86 to 2.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.19, I² = 42%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>P = 0.62, I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR (TwHF + prednisone + CPA versus prednisone + CPA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (150)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.002, RR = 1.65 (1.21 to 2.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.60, I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PR (TwHF + prednisone versus prednisone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (143)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.72, RR = 0.89 (0.47 to 1.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.73, I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>P = 0.53, I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PR (TwHF + prednisone + CPA versus prednisone + CPA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (150)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.21, RR = 0.67 (0.35 to 1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.89, I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR+PR (TwHF + prednisone versus prednisone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (143)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.04, RR = 1.22 (1.01 to 1.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.35, I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>P = 0.72, I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR+PR (TwHF + prednisone + CPA versus prednisone + CPA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (150)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.008, RR = 1.29 (1.07 to 1.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.71, I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR (sensitivity analysis for diagnostic criteria)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (201)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.02, RR = 1.50 (1.07 to 2.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.23, I² = 31%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> ‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PR (sensitivity analysis for diagnostic criteria)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (201)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.47, RR = 0.83 (0.49 to 1.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.86, I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> ‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR+PR (sensitivity analysis for diagnostic criteria)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (201)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.006, RR = 1.26 (1.07 to 1.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.56, I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> ‐‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>CPA: cyclophosphamide; FRNS: frequently relapsing nephrotic syndrome; NA ‐ Not applicable; TwHF: <i>Tripterygium wilfordii</i> Hook F; CR: complete remission; PR: partial remission; CR+PR: complete or partial remission </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Subgroup and sensitivity analyses comparing Tripterygium wilfordii Hook F (TwHF) with no TwHF</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/full#CD008568-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008568-tbl-0009"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Subgroup and sensitivity analyses comparing Tripterygium wilfordii Hook F (TwHF) with prednisone</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome or subgroup</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Studies (participants)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Statistical method</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Effect estimate (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Heterogeneity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Subgroup difference</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR (TwHF versus prednisone for non‐FRNS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (159)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.94, RR = 0.99 (0.73 to 1.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.90, I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>P = 0.17, I² = 47.7%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR (TwHF versus prednisone for FRNS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.13, RR = 1.60 (0.87 to 2.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PR (TwHF versus prednisone for non‐FRNS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (159)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.91, RR = 1.03 (0.60 to 1.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.85, I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>P = 0.82, I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PR (TwHF versus prednisone for FRNS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.71, RR = 1.07 (0.69 to 1.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR+PR (TwHF versus prednisone for non‐FRNS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (159)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.93, RR = 0.99 (0.86 to 1.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.78, I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>P = 0.06, I² = 71.7%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR+PR (TwHF versus prednisone for FRNS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.04, RR = 1.38 (1.01 to 1.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR (TwHF versus prednisone for non‐IgAN)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (187)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.42, RR = 1.13 (0.84 to 1.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.55, I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>P = 0.53, I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR (TwHF versus prednisone for IgAN)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.74, RR = 0.89 (0.44 to 1.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PR (TwHF versus prednisone for non‐IgAN)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (187)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.98, RR = 1.01 (0.63 to 1.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.94, I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>P = 0.51, I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PR (TwHF versus prednisone for IgAN)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.46, RR = 1.50 (0.51 to 4.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR+PR (TwHF versus prednisone for non‐IgAN)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (187)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.53, RR = 1.06 (0.89 to 1.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.20, I² = 35%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>P = 0.94, I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR+PR (TwHF versus prednisone for IgAN)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.70, RR = 1.08 (0.74 to 1.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR (TwHF versus prednisone for adults)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (186)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.55, RR = 1.10 (0.81 to 1.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P=0.48, I²= 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>P = 0.91, I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR (TwHF versus prednisone for elderly)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.87, RR = 1.05 (0.56 to 1.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PR (TwHF versus prednisone for adults)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (186)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.62, RR = 1.12 (0.71 to 1.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.93, I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>P = 0.53, I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PR (TwHF versus prednisone for elderly)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.62, RR = 0.71 (0.18 to 2.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR+PR (TwHF versus prednisone for adults)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (186)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.37, RR = 1.06 (0.93 to 1.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.23, I² = 31%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>P = 0.60, I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR+PR (TwHF versus prednisone for elderly)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.80, RR = 0.95 (0.62 to 1.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR (TwHF versus prednisone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (159)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.94, RR = 0.99 (0.73 to 1.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.90, I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>P = 0.17, I² = 47.7%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR (TwHF + CSA versus prednisone + CSA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.13, RR = 1.60 (0.87 to 2.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PR (TwHF versus prednisone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (159)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.91, RR = 1.03 (0.60 to 1.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.85, I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>P = 0.82, I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PR (TwHF + CSA versus prednisone + CSA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.71, RR = 1.07 (0.69 to 1.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR+PR (TwHF versus prednisone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (159)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.93, RR = 0.99 (0.86 to 1.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.78, I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>P = 0.06, I² = 71.7%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR+PR (TwHF + CSA versus prednisone + CSA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.04, RR = 1.38 (1.01 to 1.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR (sensitivity analysis for diagnostic criteria)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (137)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.40, RR = 1.17 (0.81 to 1.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.42, I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> ‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PR (sensitivity analysis for diagnostic criteria)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (137)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.65, RR = 1.14 (0.65 to 1.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.70, I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> ‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CR+PR (sensitivity analysis for diagnostic criteria)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (137)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.19, RR = 1.16 (0.93 to 1.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.32, I² = 11%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> ‐‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>CSA: cyclosporine; IgAN: immunoglobulin A nephropathy; FRNS: frequently relapsing nephrotic syndrome; NA ‐ Not applicable; TwHF: <i>Tripterygium wilfordii</i> Hook F; CR: complete remission; PR: partial remission; CR+PR: complete or partial remission </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Subgroup and sensitivity analyses comparing Tripterygium wilfordii Hook F (TwHF) with prednisone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/full#CD008568-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008568-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">TwHF versus no TwHF</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Complete remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [1.18, 1.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Partial remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.49, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Complete or partial remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [1.10, 1.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Urinary protein excretion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Serum albumin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Serum creatinine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Liver transaminase elevation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Leukopenia or bone marrow suppression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">TwHF versus no TwHF</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/references#CD008568-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008568-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">TwHF versus prednisone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Complete remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.83, 1.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Partial remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.69, 1.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Complete or partial remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.92, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Liver transaminase elevation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.16, 14.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Leukopenia or bone marrow suppression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.45 [0.62, 176.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Elevated blood pressure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.02, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Elevated blood glucose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.06, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Femoral head necrosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.01, 3.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 Infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.03, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7 Psychosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.01, 0.75]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">TwHF versus prednisone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/references#CD008568-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008568-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">TwHF versus CPA</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Complete remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.82, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Partial remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.46, 2.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Complete or partial remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.90, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Urinary protein excretion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Serum albumin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Serum creatinine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Gastrointestinal discomfort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.24, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Liver transaminase elevation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.13, 3.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Menstrual disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.40, 4.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.08, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5 Hair Loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.02, 0.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6 Haemorrhagic cystitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.01, 2.38]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">TwHF versus CPA</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008568.pub2/references#CD008568-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008568.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD008568-note-1209">Español</a> </li> <li class="section-language"> <a class="" href="ja#CD008568-note-1207">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD008568-note-1206">한국어</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD008568-note-1208">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008568\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008568\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008568\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008568\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008568\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008568\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008568\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008568\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008568\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008568\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008568\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008568\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008568\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008568\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008568\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008568\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008568\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008568\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PSzzz2OT&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008568.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008568.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008568.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008568.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008568.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718768190"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008568.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718768194"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008568.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dd8653816935f',t:'MTc0MDcxODc2OC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 